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Abstract 
The human papilloma virus (HPV) is the most frequent cause of sexually transmitted 
diseases (STDs) and cancers for U.S. adults. The Affordable Care Act (ACA), enacted in 
2010, eliminated copay expenses for childhood immunizations and expanded access to 
health care. The purpose of this secondary data analysis study was to determine if there 
was an association between ACA and the usage of HPV vaccine among adolescent 
females in Georgia. Data concerning HPV vaccinations from 2011 to 2015 were obtained 
from the National Immunization Survey-Teen dataset. Andersen’s BM of health care use 
was applied to ascertain the factors that enhanced the usage of HPV vaccine. Multiple 
logistic regression analysis was used to determine if there was any association between 
ACA and HPV vaccination. The study results showed a significant association between 
ACA and provider visit (p<.05). Also, provider visit was significantly associated with 
HPV vaccination rate (p<.05). Adolescent females with health insurance had a higher rate 
of provider visit after the passage of ACA. From 2011 to 2015, 87.2% of insured 
adolescent females visited their provider. The rate of HPV vaccination increased among 
the insured adolescent females who visited the provider from 35.3% in 2011 to 53.9% in 
2015. Provider visit was identified as the most influencing factor that enhanced usage of 
HPV vaccine. The knowledge gained from the results contributed to social change by 
providing insight on how, through increased provider visits, ACA has improved the HPV 
vaccination rate among teenage females in Georgia. The conclusion will assist in 
developing effective strategies and policies that will achieve the Healthy People 2020 
goal of 80% of herd immunity against HPV.  
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Chapter 1: Introduction to the Study 
Introduction 
Human papilloma virus (HPV) infections and related cancers are health problems 
that are of concern to public health. HPV remains the most common cause of sexually 
transmitted disease (STD) in the United States among males and females (Dunne et al., 
2014; National Cancer Institute, 2015; Sun, Chang, & Rutherford, 2013). About 79 
million of the U.S. population is infected by at least a specie of the virus, while 14 
million individuals acquire the infection annually (Dunne et al., 2014).   
There are more than 150 types of HPV, of which 40 species are the primary cause 
of infections of the anogenital area and mucosa of the body (Dunne et al., 2014). The 
mucosal HPV are categorized as oncogenic (high-risk HPV) Types 16 and 18 or low-risk 
(Types 6 and 11; Dunne et al., 2014). The oncogenic types cause cancer of the cervix, 
vulva, vagina, penis, anus, and various oropharyngeal cancers (Arain, 2015). Anogenital 
warts and respiratory papillomatosis result from infection by low-risk HPV (Centers for 
Disease Control [CDC], 2015). Longstanding infection can lead to various cancers and 
diseases (National Cancer Institute, 2014). Globally, the most prevalent oncogenic strains 
of the virus HPV16 and HPV18 cause more than 400,000 cases of cancer and 22,000 case 
of cancer in the United States annually (National Cancer Institute, 2014). 
In the developmental stage of adolescence, health behaviors that are formed can 
have an immediate and long-term effect in adulthood (Tebb, Sedlander, Bausch, & 
Brindis, 2015). Adolescents can engage in sexual risk behaviors that result in STDs 
(CDC, 2015). Youths, 15 to 24 years, are found to have 50% of the 20 million new cases 
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of sexually transmitted infections (STI) in the United States yearly (CDC, 2015). Among 
females, one in four are sexually active adolescent girls identified as having an HPV-
related STD (CDC, 2015). The risk of exposure to STIs increases due to multiple sex 
partners (CDC, 2015). Vaccination of adolescents before being sexually active was noted 
to be effective in the prevention of HPV-related infections and cancers. Dunne et al. 
(2014) pointed out that the present and impending challenges in the prevention of HPV 
infections and cancers lie in increasing coverage for vaccination. Shen et al. (2014) 
reported that the rate of HPV vaccination among adolescents is lower among those facing 
cost-sharing for vaccination. Eliminating cost-sharing for the HC vaccine will increase 
compliance and vaccine uptake (Shen et al., 2014). 
The Affordable Care Act (ACA) was enacted in 2010, and a significant provision 
of this law is no cost-sharing for preventive services, which included childhood 
immunizations such as the HPV vaccine. Despite this rule, the HPV vaccination rate in 
Georgia for adolescent females, in 2015, was 54.4% for one dose series, 38.7% for 
second dose, and 32.3% for three doses (Georgia Department of Health, 2016). Although 
the HPV vaccination increase was noted in first dose series, the completion of the series 
remained low, reflecting a significant gap in attaining the Healthy People 2020 goal of 
80% of HPV vaccine coverage for adolescent females. 
Underwood et al. (2015) identified that Georgian teens with private insurance in 
high school are less likely to complete the three doses of HPV vaccine compared to those 
who have Medicaid coverage. No study was conducted to evaluate if the ACA influenced 
the use of HPV vaccination among adolescents in Georgia. There was a need for this 
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study to explore if ACA had an impact on HPV vaccine use by evaluating the trend of 
vaccination from 2011 to 2015 after the ACA enactment in 2010. 
 HPV vaccine is one of the clinical preventive services recommended for 
adolescents starting at age 9 because it was proven to be effective in the prevention of 
HPV-related infections and cancers, if given before being sexually active. This vaccine is 
covered under ACA without cost-sharing, which is a significant provision of ACA for 
preventive services in both private and public insurance plans. However, HPV 
vaccination rate is still low compared to other recommended childhood immunizations 
and the Healthy People 2020 goal for adolescent females in Georgia. Determining if 
ACA influences vaccine uptake will provide knowledge about why the underuse of HPV 
vaccine still exists. This knowledge can be used to design programs that will improve 
use, with the goal of preventing HPV-related diseases and cancers through policy and 
clinical practice.    
Chapter 1 consists of the background of this study, problem statement, the 
purpose of conducting the research, research questions, hypotheses, and the theoretical 
framework. Additional sections of this chapter include the nature of the study/research 
design, assumptions, scope and delimitations, limitations, significance, summary, and 
transition to Chapter 2. 
Background of Problem 
Underuse of HPV vaccine among adolescents is a public health concern as the 
HPV virus is the most typical cause of STDs in the United States among males and 
females (Dunne et al., 2014; National Cancer Institute, 2015; Sun et al., 2013). In United 
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States, youths 15 to 24 accounted for 50% of the 20 million new STIs yearly (CDC, 
2015). Also, one in four sexually active adolescent females have an STD that is caused 
by HPV (CDC, 2015). The risk of exposure to HPV increases with multiple sex partners 
(CDC, 2015). Satterwhite et al. (2013) identified the most common STIs as chlamydia, 
gonorrhea, syphilis, herpes, HPV, hepatitis B, HIV, and trichomonas. Satterwhite et al. 
revealed that HPV STIs are the most frequent in the United States, with more adolescents 
and young adults acquiring HPV. Satterwhite et al. reported that approximately 110 
million STIs are found among this population. Young women and men between the ages 
15 to 24 (22.1 million) had 20% of infections (Satterwhite et al., 2013). Of the 19.7 
million STIs reported, 50% of them were in this age group (Satterwhite et al., 2013). 
HPV infections were also prevalent in this population (Satterwhite et al., 2013). 
Young adults are prone to contracting STDs because they tend to have multiple 
and older partners and they engage in unsafe sex practice (Nguyen et al., 2016). In a 
study involving 18,984 adolescents between the ages of 13 to 17 years, Nguyen et al. 
(2016) indicated that 56% of young adults reported having >2 partners, and 54% had 
concurrent partners. Also, 69% of young adults had sex with older partners, while 35% 
had sex outside of their ethnic group (Nguyen et al., 2016).  
The burden of HPV infections in the United States is high, as 70% of cervical 
cancers are linked to HPV (Arain, 2015). There is also an increased incidence of 
oropharyngeal and anal cancers, including disparities in the cancer incidence rate (Jermel 
et al., 2013). The high-risk strains of HPV are the primary cause of “vaginal cancers, 55 
percent, anal cancers, 79 percent and 62% of oropharyngeal cancers” (Dunne et al., 2014, 
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p. 69). The annual projected new incidence of cancers associated with HPV in the United 
States is 26,000 (CDC, 2014). About 17,000 of the new cases of cancer will occur in 
females, while 9,000 will occur in males (CDC, 2014). About 79 million people in the 
United States are infected with HPV, while 14 million of the population acquire the 
infection yearly (Dunne et al., 2014). 
 Arain (2015) indicated that the risk of HPV transmission increases with first 
sexual intercourse at an early age and multiple sexual partners, resulting in the high 
incidence of cervical cancer. Although the rate of cervical cancer is decreasing in the 
United States, the rate of cervical cancer among African Americans and Hispanic 
Americans is still high (Arain, 2015). When compared to European American women, 
African American women have a higher incidence rate of cervical cancer (34%) and 
mortality rate (Arain, 2015). Also, Hispanic American women have approximately 50-70 
times increased incidence of cervical cancer and mortality rate when compared to non-
Hispanic White women (Arain, 2015).   
There is a marked rise, and frequent occurrence, of HPV16-induced 
oropharyngeal cancer (head and neck cancer) in the United States, and transmission was 
noted to be through deep kissing and urogenital sex (Gillison et al., 2012; Nguyen et al., 
2016). Researchers who examined the HPV link with oral pharyngeal cancer identified 
high-risk sexual behaviors resulting in HPV that were comprised of multiple sex partners 
and starting sexual intercourse at an early age (Gillison et al., 2012; Nguyen et al., 2016; 
Sivasithamparam, Visk, Cohen, & King, 2013). Singhi and Westra (2010) analyzed 256 
head and neck carcinomas and revealed that 182 (71%) of the tumors were HPV positive. 
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In a cross-sectional study conducted to ascertain the prevalence of oral HPV infection in 
the United States from 2009–2010 in both males and females from ages 14 to 69, Gillison 
et al. (2012) reported the oral HPV infection was 6.9%. Nguyen et al. (2016) claimed 
increased incidence of HPV 16 infection in 2,824 oropharyngeal cancers, reported in 23 
U.S. studies. HPV 16 was identified in 60.2% of the sampled group (Nguyen et al., 
2016). 
There is a financial burden related to HPV-related infections and cancer. About 
1.7 billion dollars is spent annually on HPV-related medical expenditures (Owusu-Edusei 
et al., 2013). The expenses included 485 million spent on cancers associated with HPV 
and 288 million spent on genital warts (Owusu-Edusei et al., 2013). In 2010, the annual 
estimate of health expenses for the prevention and remedy of diseases caused by HPV in 
the United States was $8.0 billion (Chesson et al., 2012). About $6.6 billion (82.3%) was 
spent on routine screening for cervical cancer and follow-up check-ups (Chesson et al., 
2012). In addition, $1.0 billion (12.0%) was spent on both cervical cancer ($0.4 billion), 
and $0.3 billion was spent on oropharyngeal cancer (Chesson et al., 2012). Also, $0.3 
billion (3.6%) was spent on treating genital warts, while $0.2 billion (2.1%) was spent on 
treating recurrent respiratory papillomatosis (Chesson et al., 2012). Dunne et al. (2012) 
denoted that the cost of HPV-associated diseases and cancer remained a problem for 
public health. To reduce the burdens, a vaccination-integrated approach must involve 
clinical medicine, in combination with public health and public policy (Dunne et al., 
2012). 
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In Georgia, the Comprehensive Cancer Registry reported 400 cases of cervical 
cancer annually from 2008-2012, and 140 women died from cervical cancer from 2007 to 
2012 (Berzen, McNamara, Bayakly, O’Connor, & Crane, 2016). African American 
women are more likely to die of cervical cancer than European American women (Berzen 
et al., 2016). One in 154 females in United States will develop cervical cancer in their 
lifetime (Berzen et al., 2016). The rate of cervical cancer in Georgia was 7.7 compared to 
the national rate of 7.6 (National Cancer Institute, n.d.). The rate of oropharyngeal cancer 
in Georgia at the same period was 12.1, while the national rate was 11.3 per 100,000 
population per year (National Cancer Institute, n.d.).   
The Georgian mortality rate for cervical cancer, oral cavity, and pharyngeal 
cancers is 2.6 per 100,000 compared to the national rate of 2.3 and 2.4 per 100,000 
respectively (National Cancer Institute, n.d.). There is a higher incidence and mortality 
for both cervical and oropharyngeal cancers in Georgia (National Cancer Institute, n.d.). 
Even with the increased cancer incidence in Georgia, the HPV vaccination rate is still 
below the Healthy People 2020 goal. Underuse of the vaccine was reported in 2010 based 
on Jemel et al.’s (2013) study, which showed that only 32% of adolescents 13–17 years 
received three doses of the HPV vaccine. Vaccination rate was significantly lower among 
the uninsured found in some Southern states where cervical cancer rates were highest 
(Jemel et al., 2013). Ferrara, Audreya, Trotterb, and Hickman (2015) indicated that 
individuals without health insurance are less likely to receive an HPV vaccination. 
Georgia is one of the Southern states where the cervical cancer rate is above the national 
average (National Cancer Institute, n.d.), while the HPV vaccination rate remains low. 
8 
 
ACA is an insurance mandate enacted by President Obama in 2010. A significant 
mandate of this law is no cost-sharing for preventive services, such as childhood 
immunizations (Eno, Mehalingam, & Nathaniel, 2016). Childhood vaccines from birth 
until the age of 18 are covered fully under the ACA as preventive services (Eno et al., 
2016). Under the ACA, the HPV vaccine is covered 100% without any out-of-pocket 
expenses. The ACA established a mandatory fund for community health centers (CHCs) 
and school-based health care clinics (SBHCs) to provide health care services to the 
uninsured and underserved populations with the aim of expanding access to preventive 
services (Curtis et al., 2014). Insurance coverage will decrease out-of-pocket expenses as 
a way to enhance vaccination uptake (Curtis et al., 2014). 
The HPV vaccine is one of the preventive immunization vaccines for children 
from birth to age 18 that is covered under the ACA without cost-sharing (Eno et al., 
2016; Kaiser Family Foundation [KFF], 2016). The HPV vaccine was recommended 
from age 11 to 12 because it was proven to be effective in the prevention of HPV 
infections and cancers; however, the vaccination uptake remained low in the United 
States (Rahman, Islam, & Berenson, 2015). The HPV vaccination is one of the clinical 
preventive services endorsed by the Advisory Committee on Immunization Practices 
(ACIP; Curtis et al., 2014). HPV vaccine can be given to girls at age 9, but girls and adult 
women 13 to 26 years who did not get started or complete the series can catch up at this 
period (CDC, 2015). 
 Despite the recommendation by ACIP, in Georgia as of 2015, only 54.4% of 
adolescent females received a dose of HPV vaccine, while 32.3% received three doses or 
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completed the series (Georgia Department of Health, 2015). The Healthy People 2020 
goal for the adolescents is to attain 80% HPV vaccine coverage (Healthy People, 2016). 
Dunne et al. (2014) noted that the present and future tasks in preventing HPV infections 
and cancers lie in increasing vaccination coverage. This study is needed to explore if 
ACA has an impact on HPV vaccine use rate among adolescent females in Georgia, as 
the CDC's Community Guide on Preventive Services systematic suggested that insurance 
coverage will decrease out-of-pocket expenses as a way to enhance vaccination uptake 
(Curtis et al., 2014). 
In this study, I explored if insurance coverage without cost-sharing of preventive 
services had an influence on the use of HPV vaccine by monitoring the trend of HPV 
vaccination rate after the enactment of ACA from 2011 to 2015. The factors that affected 
the use of health services were assessed to identify the one that had the most significance. 
The knowledge this study furnished will be useful in designing programs that will 
prevent HPV-related diseases and cancers through an integrated approach to policy and 
clinical practice. 
Problem Statement 
In spite of the implementation of the ACA with no cost-sharing for childhood 
immunizations, such as HPV vaccine, the use of the HPV vaccine remained below the 
Healthy people 2020 target for adolescent females in Georgia. Scholars reported that the 
HPV virus is the most prevalent cause of STDs among teenage females in the United 
States (CDC, 2015; Satterwhite et al., 2013) and cancers in adulthood (Dunne et al., 
2014; National Cancer Institute, 2015; Sun et al., 2013). Despite the high prevalence of 
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HPV-related diseases and cancers, vaccine use remained low in the United States (Dunne 
et al., 2014; Jermel et al., 2013). Jemel et al. (2013) reported that only 32% of adolescent 
females aged 13–17 years received three shots of the HPV vaccine in 2010. Dunne et al. 
(2014) indicated that the HPV vaccination coverage for adolescent girls remained far 
below the Healthy People 2020 goal of 80%, compared to other vaccines recommended 
for this age group. Underwood et al. (2015) reported that adolescents with private 
insurance were more likely to complete three doses of the HPV vaccine. As of 2015, only 
54.4% of adolescent females in Georgia received a dose of HPV vaccine, while 32.3% 
received three doses (Georgia Department of Health, 2015). The cost of the vaccine was 
identified as a barrier to use; eliminating this barrier can enhance uptake of vaccine (Shen 
et al., 2014). Underuse of the HPV vaccine among adolescents and high incidence rate of 
HPV-associated cancers heighten the need for prevention efforts to increase coverage for 
the vaccine (Jermel et al., 2013). Primary prevention of HPV through childhood 
immunization is necessary for reducing HPV-associated cancers and infections (Jermel et 
al., 2013). One of the strategies that was created to increase the use of vaccine 
compliance was health insurance reform that eliminated or minimized out-of-pocket 
expenses for the immunization (Dunne et al., 2014). ACA expanded primary and 
preventive services by the expansion of Medicaid and the reauthorization of the State 
Children's Health Insurance Program (SCHIP; Lathrop & Hodnicki, 2014). Adolescents 
can receive HPV immunization through well-child visits to providers, although more 
visits are necessary to complete the required doses (Shen et al., 2014). Eliminating cost-
sharing for the HPV vaccine will increase access to provider visits, compliance, and HPV 
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vaccination rate. Although the ACA was implemented in 2010, scholars have not 
examined if there is an association between health care reform (ACA) with no cost-
sharing with the HPV vaccination rate among adolescent females in Georgia. There was a 
lack of information on whether ACA affected the use of the HPV vaccine among 
adolescent females in Georgia. Also, no scholar attempted to statistically quantify if there 
was an association between ACA and the HPV vaccination rate among teenage females 
in Georgia.   
Purpose of the Study 
The purpose of this study was to explore if there was an association between the 
ACA and the rate of HPV vaccine among adolescent females in Georgia. HPV 
vaccination was one of the clinical preventive services recommended for adolescents by 
the AICP. The low HPV vaccine may have occurred due to cost resulting in out-of-
pocket expenses for those with private insurance and for the uninsured. Scholars have not 
examined if insurance coverage through ACA influenced the HPV vaccine uptake in 
Georgia. In this study, I addressed this gap by statistically quantifying if an association or 
relationship existed by examining the trend of HPV vaccination from 2011 to 2015 after 
the enactment of ACA. The target population was adolescent females 13 to 17 years of 
age living in Georgia. I employed a quantitative design using secondary data. Data on the 
HPV vaccination from 2011 to 2015 were obtained from the National Immunization 
Surveys (NIS) Teen data. The variables evaluated were ACA insurance coverage 
(independent variable) and the HPV vaccination rate (dependent variable). The covariate 
variables were race or ethnicity and the rate of provider visit. The knowledge this study 
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provided is beneficial in in designing programs that aim to increase the use of HPV 
vaccine. The goal is to prevent HPV-related diseases and cancers, including attaining the 
Healthy People 2020 goal of 80% herd immunity of HPV through policy and clinical 
practice.  
Research Questions and Hypotheses 
RQ1: Is there any association between ACA with no cost-sharing and the HPV 
vaccination rate among adolescent females in Georgia? 
H01: There is no association between ACA with no cost-sharing and the HPV 
vaccination rate among adolescent females in Georgia.  
Ha1: There is a significant association between ACA with no cost-sharing and the 
HPV vaccination rate among adolescent females in Georgia. 
RQ2: Is there any association between ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia? 
H02: There is no association between ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia. 
Ha2: There is an association between ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia.  
RQ3: Is there any association between provider visits and the HPV vaccination 
rate among adolescent females in Georgia? 
H03: There is no association between the provider visits and the HPV vaccination 
rate among adolescent females in Georgia. 
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Ha3: There is an association between the provider visits and the HPV vaccine 
vaccination rate among adolescent females. 
RQ4: As Georgia did not expand Medicaid under ACA, is there any association 
between race and the HPV vaccination rate among adolescent females in Georgia? 
H04: There is no association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
Ha4: There is an association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
Conceptual Framework 
The theoretical framework applied to this study was Andersen's behavioral model 
(BM). This behavioral model has been used to study the use of health services. In the 
BM, there are three factors that result in the use of health services: predisposing, 
enabling, and need factors (Babitsch, Gohl, & Lengerke, 2012). The predisposing factors 
consist of demographics (age and sex), social factors (education, occupation, ethnicity, 
and family status), and mental factors (health beliefs( Babitsch et al., 2012). Enabling 
factors are comprised of conditions that enable the use of health services, such as income, 
access to health insurance coverage, available regular source of care, transportation, 
provider, wait time, the location of health facility, and health policies (Babitsch et al., 
2012). The need factors can be an individual perceived need, which is the use of clinical 
preventive services, such as the HPV vaccine that prompted the provider visit (Babitsch 
et al., 2012). This theoretical framework was ideal for this study because it is appropriate 
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in examining the use of health services, and the HPV vaccine is one of the clinical 
preventive services provided. 
The constructs in Andersen's BM applied to this study were predisposing factor 
(race/ethnicity); enabling factors (health insurance coverage and regular source of care 
(provider visit); and perceived need (HPV vaccine), as perceived need results in visiting 
the provider for vaccination. The variables that pertained to this study were race 
(predisposing factor), insurance coverage under ACA and provider visit (enabling factor), 
and HPV vaccine (based on the perceived need to vaccinate). 
The ACIP recommended for adolescents to receive the vaccine at ages 11-12. 
These variables were assessed to ascertain if there was any association between them and 
the rate of HPV vaccine use. Investigating these variables helped in determining which 
factor had the most significant influence on the usage of HPV vaccine among the target 
population. The outcome may help in making ACA provisions and mandates that 
enhance use of HPV vaccine. 
Nature of the Study 
In this study, I employed a quantitative approach that involved secondary analysis 
of the NIS, NIS-Teen data, available for public use. I retrospectively compared the trends 
of insurance coverage, alongside the HPV vaccination rate from 2011–2015, to ascertain 
association. As the data were collected in a natural setting of the participant human 
population, the quasi-experimental design of secondary analysis was appropriate for this 
research. For this design, the HPV vaccine rate (dependent variable) was measured across 
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insurance coverage (independent variable); race/ethnicity (moderator variable); and the 
rate of provider visit, which was the mediating variable. 
The target population was adolescent females, ages 13 to 17, living in Georgia. 
This nature of the study aligned with the theoretical framework of Andersen's BM that 
aimed to identify factors that influence use of health services. It helped me to ascertain 
the factor that had the most significant impact on HPV vaccine use. Determining the 
factors that had the most significant effect will be useful in formulating strategies that 
enhance the uptake of HPV vaccine among this target population. 
Data 
Secondary data from a government archive were used for this research. The data 
were obtained through a web search of the government’s data archive: NIS, NIS-Teen 
sponsored by the CDC. Data for this study consisted of results of the survey conducted 
from 2011 to 2015. 
I monitored the trend of HPV vaccine use rate from 2011 to 2015 to ascertain if 
there was an association between insurance coverage with no cost-sharing after the 
enactment of ACA and the vaccine uptake. Also, I observed race and the rate of provider 
visit. The data obtained were used to answer the research questions to deduce if there was 
an association between the independent variables and dependent variable. Answering the 
questions helped in drawing a conclusion on whether ACA influenced the use of HPV 
vaccine, with the goal of recommending strategies that can improve use of the HPV 
vaccine. 
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Definition of Terms 
Adolescent female: A critical transitional period that includes the biological 
changes of puberty and the need to negotiate key developmental tasks, ages 10 to 19 
(Healthy People, 2014).  
Affordable Care Act (ACA): The ACA was enacted in March 2010 by President 
Obama as a federal statute with a mandate for people in the United States to obtain health 
insurance or pay monetary fines (Levy, 2016).  
Age: A pertinent stage in a person’s life (Oxford University Press, 2017). 
Health insurance coverage with no cost-sharing: A key provision of the ACA of 
2010 requiring private insurance plans to cover recommended preventive services, such 
as immunizations, without out-of-pocket expenses or copayment (KFF, 2015). 
Human papilloma virus (HPV) vaccine: A vaccine that is effective in the 
prevention of HPV-related cancers (cervix, vulva, anal, and oropharyngeal) and diseases 
(CDC, 2016).  
Provider visit: The percentage of adolescents who had contact with a health care 
provider within a year (CDC, 2016).  
Race: A concept of human distinction based on physical characteristics, such as 
skin color, hair texture, eyes, and facial features (Takezawa, Smedley, & Wade, 2013). 
Underuse: Not being used to full capacity when benefits exceed risks (Agency for 
Healthcare Research and Quality [AHRQ], 2016). 
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Assumptions 
This study had assumptions. I assumed that the NIS-Teen nationally represented 
adolescents aged 13-17 years living in the United States. The NIS-Teen used a random 
digit dialing telephone survey of households, a combination of landline and cellular 
phone, including collecting information on vaccinations from the teens’ vaccination 
provider; these multiple data collection methods strengthened the validity of data. I also 
assumed that the staff who collected the data were adequately trained and unbiased. Also, 
I assumed that the sampling, data collection methods, and weighting procedures applied 
made the data reliable. 
Scope and Delimitations 
The main delimitation of this study was that I focused on only adolescent females 
in Georgia aged 13 to 17 years. This research was a secondary analysis of partly exported 
data from the NIS-Teen data. The outcomes of the study cannot be used for 
generalization. Also, the definition of adequate provider data used for the 2014 NIS-Teen 
estimates was revised. This revision might affect vaccination coverage estimates. Further, 
population mobility from the relocation of residence or scattering of records due to the 
use of more than one provider can result in underreporting of immunization records by 
providers. Also, a decrease in response rates increased nonresponse bias. 
Significance 
This study is significant as it provided a broader view on ACA and use of HPV 
vaccine among adolescent females in Georgia. Identifying and filling the gap in the 
literature was vital in creating a positive social change. Monitoring the trend of HPV 
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vaccination from 2011 to 2015 after the enactment of ACA helped in showing the 
magnitude of the underuse of the HPV vaccine among adolescent females in Georgia. 
Determining the association between ACA and use of the HPV vaccine produced 
knowledge that is the first step in developing strategies to enhance vaccine use. 
Dissemination of the results of this study will assist in formulating an integrated approach 
that includes clinical medicine, public health, and public policy to develop strategies that 
will improve the use of the HPV vaccine among adolescent females to attain the Healthy 
people 2020 goal of 80% herd immunity for this age group. Achieving herd immunity 
through 80% of HPV vaccination coverage will result in the prevention of HPV-related 
infections and cancers, as well as the economic burdens linked to it. Healthy adolescents 
result in healthier adults, community, and an entire population. 
The purpose of this study was to explore if the ACA impacted the use of the HPV 
vaccine among adolescent females ages 13 to 17 years in Georgia. I examined the factors 
that influenced the use of HPV vaccine, a clinical preventive service, by using Andersen's 
BM. Determining the factors that affected the use of HPV vaccine services may help in 
the formulation of strategies that will enhance the uptake of the vaccine. The information 
derived from this study provided insight on the factors that had the most influence in the 
use of HPV vaccine. The outcome resulted in knowledge on policies that can be 
beneficial in designing programs that center on enhancing the uptake of the HPV vaccine 
among this population, to attain the Healthy people 2020 goal of 80% herd immunity. 
The goal is to prevent HPV-related cancers and diseases through policy and clinical 
practice. 
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Positive Social Change 
There are many potential positive social changes that may result from the 
information obtained from this study. The results of this study may help in developing 
strategies that will enhance the use of vaccine to attain the Healthy People 2020 goal of 
80% herd immunity. The social change implications include knowledge in formulating 
policies by decision makers, researchers, and program developers to find ways to 
optimize the use of the HPV vaccine and to improve the health of the population through 
achievement of herd immunity. The long-term outcome will include decreasing the rate 
of HPV-related cancers, such as cervical cancer, and minimizing the financial burden 
related to HPV-related cancers and diseases, including reducing the percentage of STIs 
associated with HPV infections. An additional outcome will be herd immunity and 
improved health of individuals and various communities in Georgia. 
Summary 
There is a high prevalence of the HPV virus, a leading cause of STDs. Most of the 
infections are found in youths aged 15 to 24 years, who are responsible for half of the 20 
million new STDs yearly. There are cancer burdens and an increased prevalence of oral 
pharyngeal cancers linked to HPV. Irrespective of higher incidence, the HPV vaccine use 
rate in Georgia among adolescent females was 54.4% for a dose of HPV vaccine, while 
32.3% completed the series in Georgia in 2015. In Georgia, insurance coverage or no 
coverage was a barrier to obtaining the HPV vaccine. The provisions of ACA included no 
cost-sharing for preventive services and instituted a new compulsory fund for CHCs to 
provide health care services to the uninsured and underserved populations with the aim of 
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expanding access to preventive care. The provisions allowed access and provided 
infrastructures to enhance the use of the vaccine. Exploring the factors under Andersen's 
conceptual model that influence the use of HPV vaccine helped me in identifying the 
most significant factors related to receiving the HPV vaccine. The knowledge gained will 
be useful in formulating strategies to enhance vaccine uptake. The goal is to achieve the 
Healthy People 2020 goal of 80% herd immunity to HPV. 
In Chapter 1, I introduced the study, background, problem statement, purpose of 
the study, research questions and hypotheses, and the conceptual framework. I also 
provided the nature of the survey, definitions, assumptions, scope and delimitations, and 
limitations. I concluded by stating the significance, implications for positive social 
change, and summary.  
In Chapter 2, I will present the review of literature that supports the study. I will 
outline the significance of this study and discuss ACA, HPV burden, and underuse of 
HPV vaccine among adolescents. 
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Chapter 2: Literature Review 
Introduction 
HPV is the most frequent cause of STDs in the United States (Dunne et al., 2014). 
About 79 million members of the U.S. population is infected with at least a strain of the 
virus, while 14 million individuals acquire the infection annually (Dunne et al., 2014). 
Longstanding infection can result in various cancers and diseases (National Cancer 
Institute, 2014). 
Youths ages 15 to 24 account for half of the 20 million new STIs yearly, and one 
in four sexually active adolescent females have an STD, such as HPV (CDC, 2015). The 
risk of HPV exposure increases when an individual has multiple sex partners (CDC, 
2015). Latent effects of infections can result in genital warts and cervical and 
oropharyngeal cancers, which can be prevented through the HPV vaccination during 
adolescence (Dunne et al., 2014). Vaginal and vulvar cancers in women, anal types of 
cancer, and penile cancers in men can result later in life due to HPV (Meites, Kempe, & 
Markowitz, 2016). In Georgia, the prevalence rate of cervical and oropharyngeal cancers 
linked to HPV was above the national average at 7.7% and 12.1% respectively (Berzen et 
al., 2016). The mortality rate for cervical cancer, oral cavity, and pharynx cancers were 
2.6% (National Cancer Institute, n.d.).   
Despite the higher incidence and mortality for both cervical and oropharyngeal 
cancers in Georgia, the HPV vaccination rate is below the Healthy People 2020 goal of 
80% herd immunity. Based on the data from the 2015 NIS-Teen, first HPV vaccine 
uptake among adolescent females was 54.4%, but decreased to 38.7% for second dose 
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and 32.3% for third dose (Georgia Department of Health, 2015). In the United States, for 
the same period among adolescent females, ≥1 dose HPV was 62.8 %, ≥2 HPV dose was 
52.2%, and ≥3 dose HPV was 41.9% (Reagan-Steiner et al., 2016). 
HPV vaccine is useful in the prevention of HPV-related diseases and cancers 
(CDC, 2016). The World Health Organization (WHO) recommended that the 
quadrivalent and bivalent HPV vaccines be integrated into the national immunization 
policies, making it a public health priority for prevention (as cited in Sun et al., 2013). 
The U.S. Food and Drug Administration (FDA) approved three HPV vaccines: the 
quadrivalent (4vHPV) and 9-valent HPV vaccines (9vHPV), gardasil and gardasil 9, and 
the bivalent HPV vaccine (2vHPV) cervix (as cited in Meites et al., 2016). All of the 
three vaccines target HPV 16 or 18 that cause most of the cancers linked with HPV 
(Meites et al., 2016). Globally, these strains cause more than 400,000 cases of cancer 
yearly and 22,000 in the United States (National Cancer Institute, 2014). The bivalent 
(HPV2) vaccines safeguard against HPV Types 16 and 18 associated with 70% of 
cervical cancers and most other types of cancer (Stokely et al., 2013). HPV4 guards 
against HPV Types 6 and 11, responsible for 90% of genital warts (Stokely et al., 2013). 
In addition, 9vHPV provides defense against these and five additional types: HPV 31, 33, 
45, 52, and 58 (Meites et al., 2016). These three vaccines were approved to be given in a 
3-dose series at intervals of 0, 1 or 2, and 6 months (Meites et al., 2016). 
Based on clinical trial results in 2016, the FDA approved 9vHPV to be given to 
girls and boys between the ages of 9 through 14 years in a 2-dose series (Meites et al., 
2016). Also, the ACIP recommended that adolescents initiating HPV vaccination within 
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this age range should receive a 2-dose series (Meites et al., 2016). Adequate vaccination 
is applied if 2vHPV or 4vHPV are completed in the same 2-dose series schedule at 0 or 
6-month intervals, when the vaccination series was initiated before the 15th birthday 
(CDC, 2016). Only the 9vHPV is distributed in the United States since late 2016 (Meites 
et al., 2016). 
HPV vaccine is one of the clinical preventive services covered under the ACA for 
adolescents. ACA states that there is no cost-sharing for preventive services, such as 
childhood immunizations, from birth to age 18 years, which included the HPV vaccine 
(Eno et al., 2016). This law established a mandatory fund for CHCs and SBHCs to 
provide health care services to the uninsured and underserved populations with the aim of 
expanding access to preventive services (Curtis et al., 2014; Forsberg et al., 2014). 
Medicaid expansion was included in the law, although it was made optional by the ruling 
of the Supreme Court (Curtis et al., 2014; Eno et al., 2016; Forsberg et al., 2014). Despite 
these provisions, the use of the HPV vaccine among adolescent females remains 
suboptimal in the United States.  
Although ACA mandated no cost-sharing in both the private and government 
medical insurance plans for all childhood immunizations, including the HPV vaccine, the 
use of the HPV vaccine lagged behind the 2020 Healthy People goal of 80% herd 
immunity among adolescent females in Georgia. Underwood et al. (2015) identified that 
adolescents in high school with private insurance were at more likely to complete three 
doses of the HPV vaccine compared to others who had Medicaid coverage. Also, Jemel et 
al. (2013) noted that HPV vaccine coverage was significantly lower among the uninsured 
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in some Southern states, and Georgia was one of the states. Having private insurance 
(Underwood et al., 2015) and being uninsured (Jemel et al., 2013) were noted to be 
barriers to vaccination. Cost or out-of-pocket expenses involved in private insurance and 
the uninsured was observed to be a barrier to receiving the HPV vaccine. However, 
scholars have not explored if there is an association between insurance coverage under 
ACA with no cost-sharing and HPV vaccine use.  
The purpose of this study was to explore if the ACA had an impact on the use of 
HPV vaccine among adolescent females, ages 13 to 17, in Georgia. This exploration 
involved measuring the trend between ACA insurance coverage to the HPV vaccination 
rate from 2011 to 2015. I wished to identify the degree of the relationship between ACA 
insurance coverage and HPV vaccination. Three factors that influence the use of health 
services (predisposing, enabling, and need factors), postulated by Andersen's BM, were 
used because HPV vaccine is one of the clinical preventive services. I measured the to 
determine the association and magnitude of the problem in Georgia. Determining the 
level of relationship between ACA and use of HPV vaccine is the key to developing 
strategies to enhance vaccine usage. 
In this chapter, I reintroduce the problem statement and the purpose of the study. I 
also provide a synopsis of current literature on the significance of the problem. Other 
sections of Chapter 2 include the literature search strategy, the conceptual model of the 
study, and the literature related to key variables and or concepts. The variables are 
Georgia, ACA, HPV, risk factors, infections and cancers linked to HPV, HPV vaccine, 
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race, provider visits, predisposing, enabling, and need factors. Finally, this chapter will 
end with a summary and conclusion, including the transition to Chapter 3. 
For this research, I searched for articles at the Walden University Library and 
expanded to EBSCO (Elton B Stephens Company), PubMed, Medline, and ProQuest for 
databases relating to studies on HPC. Databases searched included Academic Search 
Complete, Cochrane Database of Systematic Reviews (CDSR), Dissertations and 
Abstracts, and PsycINFO. I also searched publishers’ databases, such as Elsevier and 
Springer. Additional searches were conducted through Google Scholar and the World 
Wide Web on relevant peer-reviewed articles. During the search, I used the following 
keywords: HPV, HPV vaccination, HPV-related cancers and infections, burden related 
to HPV infections and cancers, economic burden of HPV, ACA, preventive services under 
ACA, use of HPV vaccine, Georgia and HPV vaccine, and the theoretical model relating 
to the use of health services (Andersen's BM). During the search, the focus was on current 
articles from 2012 to 2016. 
I also conducted a search on governmental, organizational websites, and 
Britannica to obtain relevant data needed for the review. A search was made to determine 
the appropriate conceptual model applicable to this study. I decided to use the theoretical 
model relevant to health care use, which will be discussed in this chapter and the research 
design. 
Theoretical Framework 
Health care use is the use of health care services by individuals for preventing 
diseases, curing diseases, health promotion, and health maintenance (Andersen, 1968). It 
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also depicts the contact between a person's need for the health systems that help in 
assessing how the health care delivery system is being used and by whom. Health care 
use is dependent on supply based on the structure of the health system and need factors 
(Babitsch et al., 2012). Andersen's BM was the theoretical framework in this study. 
Andersen initially postulated this behavioral model in 1968, where a three-stage model 
consisting of predisposing, enabling, and need components were used to expound on the 
divergent use of medical care services by families. Andersen (1968) developed this 
framework to determine situations or factors that aid or hinder an individual's use of 
health services. According to the BM, use occurs where a person is predisposed to 
receive health services, enabling conditions that make it available for use and where there 
is perceived need to use and respond (Andersen, 1968). Each component of the model has 
subcomponents that consist of variables that are empirically measured and analyzed 
(Andersen, 1968). The interrelationship between the components and the use of health 
services were examined with the purpose of comparing and summating use of service 
(Andersen, 1968). 
Andersen's BM has been applied in various studies pertaining to health care use 
(Babitsch et al., 2012). The BM evolved as a multilevel model that incorporated both 
individual and contextual determinants of use of health services (Babitsch et al., 2012). 
The BM consists of three factors: predisposing, enabling, and need factors (Andersen, 
1968).  
The predisposing factor is used to explain the inclination to use health services by 
individuals (Aday & Anderson, 1974). Predisposing factor include demographics (age, 
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sex, race, and religion), social factors (education, occupation, ethnicity, and family 
status), and health beliefs or values pertaining to health (Aday & Anderson, 1974; 
Andersen, 1995; Babitsch et al., 2012). The components of this factor exist before the 
onset of illness (Aday & Anderson, 1974). 
According to Anderson (as cited in Hulka & Wheat, 1985), demographic factors, 
such as age and sex, are biologic-based factors that relate to the need for health services. 
Also, race or ethnicity determine health concerning disparities and can impact health care 
use (Institute of Medicine, 2006). The social factors that are defined by the occasional 
social structure are measured with education, occupation, family status, and ethnicity 
(Anderson, 1995). These characteristics influence the physical environment and the 
capability to cope with presenting problems and resources to take care of the problems 
(Anderson, 1995). Health beliefs include values, attitudes, and knowledge towards health 
and health services that can impact the perceived need for health services (Anderson, 
1995). Anderson (1995) explained how social structure could affect both the enabling 
resources and perceived need, resulting in the use of health services.  
Enabling factors involve these components: resources-personal/family and 
community (Andersen, 1995). The enabling factors are comprised of conditions that 
facilitate the use of health services, such as income, access to health insurance coverage, 
available regular source of care, transportation, provider, wait time, the location of the 
health facility, and health policies (Babitsch et al., 2012). Anderson (1995) noted that 
both personal and community resources must exist for use to occur. Penchansky and 
Thomas (1981) pointed out that income, having health insurance, and having a source of 
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care can enhance or hinder the use of medical services. Access could be measured by 
availability, accessibility, and affordability (Penchansky &Thomas, 1981). 
The need factors are the individual perceived need, based on view and experience 
on general health, functional state, and illness that prompt the use of medical services 
(Babitsch et al., 2012). The perception of health may vary for individuals, and Andersen's 
BM offers a means for summing up these variations in the consumption or use of health 
care services (Jahangir, Irazola, & Rubinstein, 2012). Anderson (1995) explained that 
perceived need is not primarily a gauge of disease, but a social phenomenon that, if 
adequately modeled, can be expounded by health beliefs and social structure. Health 
education programs could influence the perceived need for health care and the change in 
financial incentives to seek care (Anderson, 1995). 
This conceptual model evolved over the years and expanded to differentiate 
measures of possible access and realized access (Derose, Gresenz, & Ringel, 2011). The 
BM developed to incorporate environmental factors, health behavior, and health 
outcomes including equity, efficiency, effectiveness, and health and wellbeing (Derose et 
al., 2011). Also added was the significance of variables at the community level and 
factors particular to vulnerable groups or populations (Derose et al., 2011). The concept 
advanced beyond the personal level to health policy changes, environmental (rural or 
local) variables, provider supply, and the characteristics of health care system (Derose et 
al., 2011). Although there is a progression of the BM, most of its application is on the 
factors at the individual level that influence behavior in seeking care (Derose et al., 
2011). 
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The BM was applied in various studies involving use of health services in health 
systems and health, especially in the United States and in the United Kingdom (Babitsch 
et al., 2012). The BM is flexible; the variables can be tested and applied to differing 
settings (Azfredrick, 2016). In the BM, researchers can choose independent variables 
depicted in the hypothesis (Azfredrick, 2016).   
In the critique of Andersen's model, Goldsmith (as cited in Lo & Fulda, 2008) 
identified that the model did not define access in the original model posited in 1968. 
Anderson (1995) acknowledged the critique and defined access in multidimensional 
terms using potential access as the existence of enabling resources that enhance the use. 
Realized access is the use of services. Equitable access is dependent on demographic 
characteristics and needs factors (Lo & Fulda, 2008), while inequitable access results 
when the social structure, health belief, and enabling resources demarcate medical usage 
(Andersen, 1995). In using the BM in fostering equitable access, a variable must point to 
changes in policy that could cause a change in behavior (Andersen, 1995). In this study, I 
focused on policy change (ACA) to ascertain if the change in policy could have 
influenced the use of HPV vaccine. 
 Scholars who used the BM denoted the complexity of the model and did not 
convey the complexity in the production and presentation of the results (Babitsch et al., 
2012). The operationalization of the model portrayed the use of a small set of variables 
and significant differences in the categorizations about both predisposing and enabling 
factors (Babitsch et al., 2012). Scholars who used Andersen's BM denoted that the set of 
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variables used are small and that there were differences in the categorizing of variables, 
common among predisposing and enabling factors (Babitsch et al., 2012).   
Previously, Andersen's BM was applied and adapted to studies involving access 
and use of clinical preventive services across the lifespan from adolescence to the older 
population. Jahangir et al. (2012) explored the association between the three factors 
(need, predisposing, and enabling) and the use of preventive services in Argentina. This 
investigation involved logistic regression analysis of secondary data from the National 
Survey of Risk Factors between 2005 and 2009 among a cohort of 41,392 and 34,732 
individuals for both years respectively (Jahangir et al., 2012). Jahangir et al. noted that 
although the predisposing and need factors are linked with use, enabling factors (ie., 
insurance coverage or access) require public intervention. Jahangir et al. identified the 
most significant factor (enabling), such as insurance coverage and income, to address 
through policies to enhance the use of preventive services in Argentina. Aday and 
Andersen (1974) suggested that in discussing access, certain groups of people have more 
or less access based on characteristics like age, sex, or race (predisposing factor) or 
community features, such as urban versus rural (enabling factor). Health policy strives to 
alter these characteristics (i.e., income or health insurance coverage) to improve access 
for this group (Aday & Andersen, 1974). Based on the framework of Andersen’s BM, I 
demonstrated that need; enabling; and predisposing factors, including behavioral factors, 
are significantly associated with access and the use of preventive health services.  
The BM can be applied in studies relating to health care use among adolescents. 
Studies on the use of reproductive health service (Azfredrick, 2016) and use of care for 
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behavioral and emotional problems (Reijneveld et al., 2014) among adolescents used 
Andersen's BM. The BM can be used to explore the use of health services for this 
population by applying the predisposing, enabling, and need factors. Also, the BM 
reflected the flexibility of using different variables (components) within the factors that 
are pertinent to each study.  
Azfredrick (2016) applied Andersen’s BM and examined how predisposing, 
enabling, and need factors influence the use of reproductive health services among 
adolescent females in Nigeria. In this study, the predisposing factor was age (average 
14.77), enabling factors were parental support and communication and type of 
reproductive health facility, and the need factors were feelings of inadequacy and positive 
attitude about self (Azfredrick, 2016). The sampled population was comprised of 3,065 
adolescent females (Azfredrick, 2016). Azfredrick showed that parental communication, 
the enabling factor, significantly influenced the use of reproductive health service among 
this group. 
Reijneveld et al. (2014) used longitudinal data obtained from 2,230 adolescents 
between the ages of 10–19 years to assess the use of care by adolescents among 
behavioral and emotional problems, by type, and its determinants. In this study, the 
predisposing, enabling, and need factors based on Andersen's BM were applied 
(Reijneveld et al., 2014). Reijneveld et al. revealed that the use of services increased with 
age (predisposing factor), which was identified as the most influencing factor. 
Andersen's BM was used to determine which of the three factors (predisposing, 
enabling, or need) influenced the use of health care services. Weller, Minkovitz, and 
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Anderson (2003) conducted a cross-sectional study among children with special health 
care needs (CSHCN) to ascertain how sociodemographic factors and type of insurance 
influenced the use of medical and health-related services. Weller et al. showed that the 
enabling factor (insurance) was mostly associated with the use of health services. Also, 
Weller et al. indicated that children with public insurance were less likely than those 
privately insured to use medical and health-related services. 
Lo and Fulda (2008) researched the factors that affected preventive medical 
services among children ages 3–17 years of age in the United States using Andersen's 
BM. Lo and Fulda conducted a cross-sectional study involving children between the ages 
of 3–17 years. Lo and Fulda used data obtained from the National Survey of Children's 
Health. Lo and Fulda showed that household education (predisposing factor) and poverty 
level (enabling factor) significantly influenced the use of preventive care by older 
children. Lo and Fulda observed that household education (predisposing factor) and 
poverty level (enabling factor) influenced use of health care for people residing in the 
Northeast, Midwest, and South regions of the United States. 
Various factors influence the use of health care services among adolescents 
(Massey, Prelip, Calimlim, Quiter, & Glik, 2012). Coker et al. (as cited in Massey et al., 
2012) indicated that patient-provider relationship, access to services based on geographic 
location, and how adolescents perceive confidentiality play a role in how efficiently 
adolescents use preventive health care services. Use of preventive care services lagged 
among teens, even with the availability of preventive care services and insurance 
coverage (Massey et al., 2012). Massey et al. (2012) reported that scholars who studied 
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adolescents' use of preventive services focused mostly on ascertaining barriers in 
accessing health services rather than the abilities and competencies necessary to navigate 
and use the system. Massey et al. explored the knowledge, attitudes, and practices related 
to preventive and curative health care experiences and use among low-income 
adolescents who had public insurance in California. Massey et al. wished to understand 
health literacy among this group. Andersen's BM was used to explore adolescent 
interactions with the health care system and health providers (Massey et al., 2012). 
Massey et al. showed that perceived need for well-care visits influenced the use of health 
care services. However, most of the teens did not consider the need to visit a provider, 
except when they were sick or needed a sports physical (Massey et al., 2012). Massey et 
al. suggested that additional skills and competencies are necessary for this population to 
use their insurance coverage and to navigate the health care system successfully. 
Although these adolescents had insurance coverage, underlying factor like perceived 
need and health literacy competencies influenced use, despite having access (Massey et 
al., 2012).   
ACA provides access to clinical preventive services, such as the HPV vaccine, by 
instituting no cost-sharing or copay for the vaccine (Eno et al., 2016; KFF, 2016). The 
access and infrastructure of the ACA aligned with Aday and Andersen’s (1974) definition 
of access, which is both the availability of financial and health system resources within 
an area when needed. In the BM, external validation is necessary to ascertain if 
predisposing, enabling and need factors impact getting health care service (Aday & 
Andersen, 1974). When using the BM in fostering equitable access, a variable must point 
34 
 
to changes in policy that could influence change in behavior (Andersen, 1995). Aday and 
Andersen noted that the change in behavior resulting from a new policy could be 
determined by examining the rates of health care usage of particular subgroups about 
these factors (predisposing, enabling, and need) within a duration of time.  
The constructs of Andersen's BM that were applied in this study were the 
predisposing factor (race/ethnicity), enabling factors (health insurance coverage [ACA] 
and rate of provider visits), and perceived need (HPV vaccine). Perceived need for 
vaccination resulted in visiting the provider. The variables that applied to this study were 
race/ethnicity (predisposing factors), insurance coverage (ACA), provider visit (enabling 
factors), and HPV vaccine (perceived need). In this study, the variables were health 
insurance (ACA; independent variable), HPV vaccination rate (dependent variable), 
race/ethnicity (moderator variable), and the provider visit (mediating variable). These 
variables are presented below after the discussion of Georgia landscape. In addition, age 
and sex (female) variables are included in the discussion. 
Georgia Landscape 
Georgia is one of the 50 states found in the Southern part of United States, with a 
population greater than 10 million people (KFF, 2017). Georgia is the ninth most 
populous state in the United States and the third most populous state in the Southern 
United States (KFF, 2014). Georgia is the 30th largest state, consisting of 159 counties, 
of which 37 of them are rural counties (KFF, 2014). About 87% of the state population 
reside in the metropolitan areas, and 26% of the state population lives in three of its most 
populous counties: Fulton, Gwinnett, and Cobb (KFF, 2014). 
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Population Distribution 
Georgia is ethnically and racially diverse, consisting of 52% European 
Americans, 31% African Americans, 10 % Hispanic Americans, and 5% Asian 
Americans (KFF, 2017). The population of children aged 0–18 years was as follows: 
European American 42%, African American 33%, Hispanic American 17 %, Asian 
American, and other 10 % (KFF, 2017). The rate of Georgians living in poverty is 
slightly above the national average, with 22% versus 20% nationally; wide disparities 
rates exist by race/ethnicity and age (KFF, 2014). African Americans and Hispanic 
Americans are more likely to be in poverty than European Americans (KFF, 2014). Also, 
30% of Georgian children under the age of 19 years were living in poverty in 2012 (KFF, 
2014). 
Health Insurance Coverage in Georgia 
Before ACA, most of the Georgian population was covered by private health 
insurance, but by 2012, about 58% were insured under an employer plan or in the 
individual private market (KFF, 2014). Medicaid and the Children’s’ Health Insurance 
Program (CHIP) help to fill the gap in coverage, mostly for children not covered by 
private health insurance (KFF, 2014). About 40% of children in Georgia were enrolled in 
Medicaid or CHIP, known as Peach Care for Kids, in 2012 (KFF, 2014). However, 
before 2014, almost 182,000 children in Georgia who were uninsured were eligible for 
Medicaid or CHIP but did not enroll (KFF, 2014). 
36 
 
Georgia Health Care Delivery System 
The health care delivery system and safety net providers in Georgia provide 
access to primary, preventive, and acute care services for the low-income and 
underserved population (KFF, 2014). There are 29 federally qualified health centers with 
161 clinic sites in the state (KFF, 2014). In spite of the existing safety net, there are 
health professional shortage areas (HPSAs) and unmet need for care (KFF, 2014). As of 
2014, Georgia had 193 primary care HPSAs with 59% of the primary health care need 
met (KFF, 2014). ACA extended coverage to the uninsured, but Georgia was one of the 
states that refused to expand Medicaid. The safety net providers are a source of health 
care services to those newly insured or those without options for affordable health 
coverage (KFF, 2014). The effect of the ACA on health care access and health care use in 
Georgia is yet to be determined (KFF, 2014). 
HPV Vaccination Rate in Georgia 
Among adolescent females in Georgia, the HPV vaccination rate remained below 
the Healthy People 2020 goal of 80%. The ACIP recommended the HPV vaccination of 
teen girls starting at ages 11 or 12 (Stokely et al., 2013). As of 2009, before the 
enactment of ACA, the vaccination rate for adolescents ages 13–17 who had received ≥1 
HPV dose series in Georgia was 38.6% (Dorell, Stokley, Yankey, Cohn, & Markowitz, 
2010). After the enactment of the ACA in 2010, as of 2013 and 2014, the ≥1 HPV dose 
series coverage among teen females aged 13 to 17 years was 53.1% and 65.4% 
respectively (CDC, 2015). For both reported years, the HPV ≥3 doses completion among 
this group was 32.6% and 47.1% (CDC, 2015). For adolescent females in Georgia, in 
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2015, the uptake was 54.4% for ≥1 HPV dose series but was 38.7% for the second dose 
and 32.3% for the third dose (Department of Public Health, 2016). There was an 
increased rate in the initiation of first dose series from 2009 to 2014 and a marked 
decrease in rate of >10 % between 2014 and 2015 (Department of Public Health, 2016). 
For the third dose series completion among adolescent females, there was an increased 
rate of >14% between 2013 and 2014 (Department of Public Health, 2016). The third 
dose completion rate for 2015 fell below both 2014 and 2013 rates (Department of Public 
Health, 2016). A decreased rate of >14% was noted between 2014 and 2015 for HPV ≥3 
doses series completion (Department of Public Health, 2016). There arose a need to 
protect adolescent females from HPV-related diseases and cancers by optimizing the 
HPV vaccine uptake. Scholars have not determined if the ACA impacted the use of the 
HPV vaccine when the cost of the vaccine was noted as a barrier in vaccine use.  
Affordable Care Act 
The ACA was implemented in 2010 and was an important health care statute in 
the United States after the passage of Medicaid and Medicare in 1965 (Obama, 2016). 
The ACA aimed at making health care more accessible and affordable, while improving 
quality of care (Obama, 2016). The ACA was credited for reducing the uninsured rate 
from 16.0% in 2010 to 9.1% in 2015, down by 43% (Obama, 2016). 
The ACA enhanced the use of clinical preventive services, such as the HPV 
vaccine among adolescents. The ACA grandfathered private health plans to provide 
coverage with no cost-sharing (Curtis et al., 2014; KFF, 2011). The lack of out-of-pocket 
expenses were meant for four types of clinical preventive services graded as A (strong 
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recommended) or B (recommended by the United States Preventive Services Task Force; 
Curtis et al., 2014; Forsberg et al., 2014; KFF, 2011). Vaccinations recommended by the 
ACIP, such as the HPV vaccine, were included in this category (Curtis et al., 2014). The 
Health Insurance Marketplace was established to provide access to private health 
insurance for small businesses that had fewer than 50 employees and families, including 
individuals to explore options for coverage as of January 2014 (Curtis et al., 2014; 
Forsberg et al., 2014). 
More than 29 million children ages 0 to 18 years had health insurance coverage 
through Medicaid and CHIP (Forsberg et al., 2014). These were children with family 
income up to 100% of FPL, and eligibility was expanded through Medicaid or CHIP 
(Forsberg et al., 2014). Georgia was one of the states that maintained the Medicaid 
threshold for children ages 0 to 5 and 6 to 18 years (Forsberg et al., 2014). However, 
children ages 0 to 18 years with family income up to 235% of FPL could enroll in a 
separate CHIP program (Forsberg et al., 2014). These provisions created the potential to 
enhance access and the use of preventive services among adolescents (Forsberg et al., 
2014). 
No cost-sharing, as stipulated in the ACA, aligned with the CDC's Community 
Guide to Preventive Services recommendations of reducing client out-of-pocket expenses 
through insurance coverage (Curtis et al., 2014). Other suggestions included providers 
participating in the Vaccine for Children Program (VFC) and supplying vaccines to 
providers through VFC at no cost to provide access to adolescents who might have lacked 
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access (Curtis et al., 2014). These recommendations aimed at increasing the use of the 
HPV vaccine and other preventive services (Curtis et al., 2014). 
Further, the ACA provided funding for CHCs, SBHCs, and local health 
departments as a means of increasing and sustaining the infrastructure that offers safety 
net preventive and health care services (Curtis et al., 2014; Forsberg et al., 2014). The 
ACA aided in increasing access to vaccinations for underinsured children eligible for 
VFC vaccines in the CHCs (Curtis et al., 2014; Forsberg et al., 2014). In 2011, about $95 
million in federal grants was provided through the ACA to establish 278 SBHCs (Curtis 
et al., 2014). The increase benefited the low-income and uninsured adolescents with no 
medical homes (Curtis et al., 2014). In Georgia, the funding was used to establish 
community-based prevention, clinical prevention, infrastructure, and workforce, 
including research and data collection (Georgia Health Policy Center, 2012). Also in 
Georgia, the funding was used in establishing SBHCs in three counties based on the need 
assessment: Ware, Berrien, and DeKalb counties (Georgia Health Policy Center, 2012). 
All of these infrastructures improved access and quality of preventive services for 
adolescents (Curtis et al., 2014). 
The implementation of the ACA aimed at increasing access to insurance and 
preventive services coverage (Dixon & Hertelendy, 2014). The use of preventive 
services, such as the HPV vaccine, remained less optimal despite the new benefits, 
improvement in quality measurement, and recommendations (Forsberg et al., 2014). This 
study was needed to explore if the ACA had an impact on the use of the HPV vaccine 
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among adolescent females in Georgia. In this study, I evaluated the trend of the HPV 
vaccination rate from 2011 to 2015 to ascertain if the ACA impacted the vaccine usage. 
Immunization of children that aids in the eradication of diseases is a public health 
achievement. Vaccination against life-threatening diseases in children was noted to be 
cost-effective in the 20th century for medical intervention (Shen et al., 2014). Before the 
ACA, the barrier to immunization was financial, which involved out-of-pocket costs; 
about 7% of individuals with private insurance encountered cost-sharing (Shen et al., 
2014). The ACA mandated first-dollar coverage or no cost-sharing for childhood 
immunizations (birth till 18 years) recommended by the ACIP (Shen et al., 2014). 
Eliminating out-of-pocket expenses for vaccines helped to remove the financial barrier 
that deterred access to vaccination (Curtis et al., 2014; Dixon & Hertelendy, 2014; Shen 
et al., 2014). 
Shen et al. (2014) ascertained the role of cost-sharing on vaccine coverage for 
selected routine immunizations recommended for children and adolescents by modeling 
the effects of removing cost-sharing. For the study, Shen et al. employed two data 
sources: the NIS for children aged 19–35 months and the NIS-Teen for adolescents aged 
13–17 years for 2008. The insurance types included in the data were comprised of private 
insurance, Medicaid, TRICARE, CHAMPUS, and CHAMP-VA; Indian Health Services; 
Medicare; Medigap; and single-service plans and uninsured (Shen et al., 2014). The 
behavioral effect of first-dollar coverage was estimated by using the Truven Health 
Analytics 2006 MarketScan commercial claims and encounters from January 1 to 
December 31, 2006, that were comprised of 16.1 million plan members (Shen et al., 
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2014). Shen et al. also used the KFF Employer Health Benefits survey results to ascertain 
the percentage of privately insured children and adolescents who had first-dollar 
coverage or faced cost-sharing for all vaccines. The Market Scan database was used to 
identify the average cost of dose and administration for beneficiaries who received 
immunization. Shen et al. revealed that 36.9% of adolescent girls with private insurance 
received at least a dose of HPV vaccine. However, the subpopulation of teenage females 
who faced cost-sharing had a lower HPV vaccination rate of 28.9% for at least one dose 
of the HPV vaccine (Shen et al., 2014). Shen et al. found a significant drop rate of 8%. 
Also, Shen et al. showed that removing cost-sharing for HPV vaccination was projected 
to cost $5.5 million to insurers with the addition of 400,000 HPV vaccinations. However, 
Shen et al. reported that this study was done at a point in time and could not be 
extrapolated beyond this time. Data used were from separate years 2006 and 2008 (Shen 
et al., 2014). Also, Shen et al. indicated that the HPV vaccine was licensed and approved 
in 2006, and the initial uptake effect of a new vaccine could be the cause of the low 
uptake. 
Tebb et al. (2015) examined how the health care needs of teens were considered 
during the implementation phases of the ACA and the potential threats to adolescent 
confidentiality. Tebb et al. revealed that the ACA expanded health insurance access, but 
inequities in coverage and access remained. Tebb et al. reported that about 10% of 
children and adolescents were uninsured before the enactment of the ACA. However, in 
2012 after the initial implementation of the ACA, the rate of uninsured children and 
adolescents dropped to 5.5 % (Tebb et al., 2015). The increase in access was credited to 
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the elimination of the preexisting condition that impacted a proportion of adolescents 
with special health needs and Medicaid expansion (Tebb et al., 2015).  
Although an increase in access was noted among children and adolescents, Tebb 
et al. (2015) reported that most adolescents lacked access in states that opted out of 
Medicaid expansion. The mandate for the expansion of Medicaid was made optional 
based on the Supreme Court decision (Eno et al., 2016). Challenges to access for this 
group could be from fluctuations in income among low-income families that can result in 
the loss of coverage or change of insurance provider network (Tebb et al., 2015). The 
disruption in the continuity of coverage could have affected the adolescents and caused 
underuse of preventive services (Tebb et al., 2015). 
Scholars previously examined parental attitudes and provider recommendations 
regarding HPV vaccine use in Georgia. Gargano et al. (2013) claimed that both of them 
impacted the uptake of the vaccine. Also, Underwood et al. (2015) investigated the 
receipt of HPV vaccine Series 1 and 3 on both female and male adolescents, parental 
attitudes, and correlation of vaccine initiation and completion. Underwood et al. showed 
that adolescents in high school with private insurance were more likely to complete three 
doses of the HPV vaccine compared to those with Medicaid coverage. Scholars have not 
examined if the ACA had an impact on HPV vaccine use in Georgia. 
The NIS-Teen monitoring of immunization coverage among teenagers, ages 13–
17 years in the 50 states, including the District of Columbia, showed variation in 
coverage (Reagan-Steiner et al., 2016). The HPV vaccination coverage among adolescent 
females for ≥1, ≥2, or ≥3 doses increased in seven states, and the range for ≥1 HPV 
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vaccine dose was 9.4%–21% (Reagan-Steiner et al., 2016). A decrease in ≥3-dose HPV 
vaccination coverage among females was noted in Georgia when compared to 2014 
(Reagan-Steiner et al., 2016). According to Reagan-Steiner et al. (2016), in 2015, the 
HPV vaccination rate for adolescent females in Georgia aged 13–17 years was 54.4% 
(HPV-1 dose), 38.7% (HPV-2 doses), and 32.3 % (HPV-3 doses).The Healthy People 
2020 goal for this population in Georgia and  the United States is to attain 80% coverage. 
In the United States, about 24,600 newly diagnosed cancers are associated with 
two high-risk HPV types, which the currently licensed HPV vaccines target, including 
3,800 related to five high-risk HPV types included in the 9-valent HPV vaccine (Reagan-
Steiner et al., 2016). One of the goals of the ACA is to increase access to preventive 
services, which included the HPV vaccine. Yet, the use of HPV vaccine remained low in 
Georgia. In this study, I focused on ascertaining if the ACA impacted the use of the HPV 
vaccine among adolescent females in Georgia. The findings from this study can be used 
to identify strategies that can improve the use of the HPV vaccine, proven to be effective 
in preventing HPV-related diseases and cancers.  
Age and Sex (Female) 
Age is a particular stage in a person's life (Oxford University Press, 2017). 
Adolescence is a stage in life between the ages of 10 to 19 years that involves biological 
changes and the need to negotiate new developmental tasks (Healthy People, 2014). In 
the state of adolescence, health behaviors are formed that can have an immediate and 
long-term effect in adulthood (Tebb et al., 2015). 
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High-risk sexual behaviors are common among some adolescents, which result in 
STIs (CDC, 2015). Youths aged 15–24 years account for half of 20 million newly 
transmitted STDs in the United States (CDC,2015). Among adolescent females, one in 
four sexually active teens has a STD caused by HPV (CDC, 2015). The risk of exposure 
increases when people have multiple sex partners (CDC, 2015).   
The adolescents make up 13.2 % of the U.S. population, which was about 42 
million in 2014 (CDC, 2016). It is projected that this population will increase to 45 
million by 2050 (CDC, 2016). There is a concern that predisposition to HPV-related 
infections and cancers will increase with the projected population due to high-risk sexual 
behaviors among adolescent females (CDC, 2016). 
The HPV virus is the cause of cervical cancer, which is the third most prevalent 
cancer in the United States with an incidence of 1,200 new cases and 4,000 deaths 
annually (Jeudin, Liveright, Carmen, & Perkins, 2013). Immunization of adolescents 
before they become sexually active is the most effective way of preventing HPV-related 
infections. There was a need to improve the HPV vaccination rate with a focus on 
adolescent females to prevent an increase in cervical cancer in adulthood (Jeudin et al., 
2013). The ACIP recommended that adolescents receive three doses of the HPV vaccine 
at ages 11 through 12 years as a means to prevent cervical cancer (Curtis et al., 2013).  
Adolescents and young adults are at risk of having multiple sex partners who are 
older, and they are also more likely to engage in unsafe sex practices (Nguyen et al., 
2016). Ford et al. (cited in Nguyen et al., 2016) studied adolescents ages 13 to 17 years in 
in the United States and examined sexual mixing, bridging, and concurrency with 
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condom use. Ford et al. (cited in Nguyen et al., 2016) showed that more than 56% of the 
18,984 students sampled had more than two partners, and 69% had partners in varied age 
groups Ford et al. (cited in Nguyen et al., 2016) revealed that condom use was lower 
among those with multiple partners and partners in various age groups.  
Satterwhite et al. (2013) conducted a study on eight of the most prevalent STIs in 
the United States: chlamydia, gonorrhea, syphilis, herpes, human papillomavirus, 
Hepatitis B, HIV, and trichomoniasis. Satterwhite et al. showed that STIs were common 
in the United States, with a disproportionate burden among young adolescents and adults. 
Also, Satterwhite et al. revealed there were about 110 million prevalent STIs among 
women and men in the United States in 2008, and 20% of the infections (22.1 million) 
were among females and males aged 15 to 24 years. Among the 19.7 million incident 
infections in the United States in 2008, about 50% (9.8 million) were acquired by 
adolescent females and males, including youths aged 15 to 24 years (Satterwhite et al., 
2013). Adolescent girls are predisposed to HPV-related STDs due to high-risk sexual 
behaviors.  
Although one in four sexually active adolescent females has an STD caused by 
HPV (CDC, 2015), the rate of the HPV vaccine use remains low. Jemel et al. (2013) 
reported an increased incidence of two HPV-associated cancers (oropharynx and anus). 
In addition, Jemel et al. identified that the HPV vaccination rate was lower among the 
uninsured in the Southern states of United States where the highest cervical cancer rates 
were observed. In Georgia, the cervical cancer rate high, and the HPV vaccine coverage 
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rate is low. Dunne et al. (2014) noted that the challenges in preventing infections and 
cancers linked to the HPV virus depend on expanding coverage for HPV vaccination. 
Insurance coverage is essential in enhancing and influencing how teenagers use 
health services (KFF, 2011). Before the enactment of the ACA, 88% of teens aged 10 to 
18 years of age were covered by private and public insurance (KFF, 2011). About 60% of 
adolescents were covered by private insurance plans that varied in services offered, such 
as preventive services (KFF, 2011). About 9.8% of adolescents aged 12-17 lacked health 
insurance, and 4.7% had no usual source of health care (Pilkey et al., 2013).  
For teens from low-income families, Medicaid and CHIP are the public insurance 
that provide coverage (KFF, 2011). Adolescents with public insurance can receive 
services from physicians who accept the insurance (KFF, 2011). Pre-ACA, the median 
eligibility levels for children was 235% FPL (Rudowitz, Artiga, & Arguello, 2014). The 
preventive coverage under Medicaid was vast due to the Early Periodic Screening 
Diagnosis and Treatment (EPSDT) program (KFF,2011). EPSDT serves children until 
age 21 years of age, and it consists of comprehensive coverage (KFF, 2011; Rudowitz et 
al., 2014). Due to the low reimbursement rate of the program, access could be hindered 
because of a shortage of providers who accept Medicaid (KFF, 2011).  
Many adolescents are from low-income families, and more than 40% of them are 
either poor or near-poor (KFF, 2011). Low-income youth are more likely to lack financial 
resources (KFF, 2011). Financial concerns or cost (if the vaccine was not covered or the 
patient was uninsured) were identified as barriers to receiving the HPV vaccine 
(Emberger, 2015; Holman et al., 2014). 
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Under the ACA, about 4.2 million adolescents ages 10-19 who were uninsured 
qualified for health care coverage from January 1, 2014 (Pilkey et al., 2013). The state 
determined that 13.3% of the uninsured adolescents aged 10–19 years in Georgia will 
gain insurance coverage under the ACA (Pilkey et al., 2013). Pilkey et al. (2013) reported 
that insurance coverage was possible because all the states were required to provide 
Medicaid coverage for children until 19 years of age who have a family income below 
133% of the FPL. Adolescents in families with incomes more than the limits of Medicaid 
and CHIP who could not afford employer-sponsored insurance qualified for premium tax 
credits (Rudowitz et al., 2014). Close to half a million uninsured children were eligible 
for the new subsidies (Rudowitz et al., 2014). Children in families with income above 
400% FPL could obtain access to unsubsidized coverage in the marketplaces (Rudowitz 
et al., 2014). 
The cost of the entire three series of HPV vaccine was $390 (KFF, 2015). Private 
insurance could finance the vaccine, and most of the teens in the target group had private 
insurance coverage (KFF, 2015). The HPV vaccine was covered by public financing 
through the VFC program (KFF, 2015). Through a federal program called Immunization 
Grant Program, the CDC awarded grants to states, local, and territorial public health 
agencies to aid with vaccine costs (as cited in KFF, 2015). These funds could help extend 
coverage to adolescents who do not qualify for the VFC program (KFF, 2015).  
Although funding and access are available to teens, by 2011, about 47% of 
females aged 13–17 years did not receive the first recommended dose of the HPV vaccine 
(Frieden, 2014). In addition, 65% of teen girls did not complete the series or receive the 
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≥3 doses required (Frieden, 2014). Improvement in delivery and the use of the HPV 
vaccine have the potential of producing long-term benefits to help adolescents become 
healthy, productive adults (Frieden, 2014). The ACA offered opportunities to improve the 
use of clinical preventive services among adolescents through some of the provisions 
(Yeung et al., 2014). 
The KFF (2016) review on the HPV vaccine access and use in the United States 
reported that an uptake and awareness of the HPV vaccine have slowly improved. The 
KFF (2015) showed that 39.7% girls aged 13-17 years received all of the three-dose 
series in 2014, which was up from 37.6% in 2013. Also, 60% of adolescents received a 
dose of the HPV vaccine in 2014 (KFF, 2015). In addition, the HPV vaccination rates 
increased in five states, and Georgia was one of the states, between 2013 and 2014 (KFF, 
2015). However, the primary concern is the reduction in the completion of the series, 
despite a higher initiation rate. 
Although the HPV vaccine was covered by the ACA to enhance access, cost was 
noted to be a barrier that hinders vaccination uptake (Bailey et al., 2016). Under the 
ACA, health plans are required to cover recommended preventive services without 
copayment or charging deductible (Bailey et al., 2016). The costs that hindered 
vaccination uptake involved the expenses incurred by providers, such as upfront costs to 
buy the vaccine, staff, and time needed in administering the vaccine (Bailey et al., 2016). 
In addition to the expenditures was insufficient reimbursement by insurance, making it 
difficult for adolescents to obtain the HPV vaccine in the office of the primary care 
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provider (Bailey et al., 2016). Bailey et al. (2016) reported that providers are displeased 
with insurance reimbursement, irrespective of insurance type. 
The National Vaccine Advisory Committee (NVAC, 2016) reported that, 
although most of the physician professional organizations preferred for all vaccinations to 
be given in the medical homes, new strategies are required to improve the use of the HPV 
vaccine. The American Academy of Family Physicians allowed for subsequent doses of 
the HPV vaccine to be given in the medical homes if those sites were required to report 
all doses given to the state registry for vaccine (NVAC, 2016). The primary care 
physicians chose the pharmacies as the alternative site where the second and third doses 
could be given to improve the vaccination rate (NVAC, 2016). The NVAC accepted this 
recommendation and the efforts to administer the vaccine through school-located 
programs to increase access and vaccination coverage rates. The school site is ideal, as 
most adolescents are within school age, middle school to high school (NVAC, 2016). In 
spite of the recommendations, there were barriers to vaccination at the pharmacies, 
schools, and public health clinics resulting from reimbursement and compensation for the 
vaccines administered (NVAC, 2016). The NVAC claimed that the alternative settings 
mentioned often did not qualify as in-network providers and were not eligible for 
reimbursement for the vaccines administered. Alternative vaccination sites could be used 
as in-network status for payment to make these programs viable (NVAC, 2016). 
Although the schools are in-network, another challenge was billing various insurance 
plans, both public and private, as the students possibly have different insurers (NVAC, 
2016). The billing problem should be addressed, including compensating of staff due to 
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the adding of immunization services to school programs to achieve success (NVAC, 
2016). 
Moss et al. (2014) assessed the barriers to HPV vaccine provision at school by 
interviewing staff from 33 school health centers in North Carolina. Moss et al. identified 
out-of-pocket costs for children for privately purchased vaccines, costs to clinics of 
ordering and stocking privately purchased HPV vaccine, and difficulty in using the state 
immunization registry as barriers. Also, Moss et al. reported that many of the schools 
considered partnering with outside organizations on low-cost interventions to improve the 
HPV vaccine coverage for adolescents within their schools. Moss et al. revealed that 
opportunities to enhance the use of the HPV vaccine through school programs is feasible, 
but the barriers of relating to reimbursement and compensation must be addressed.  
Provider Visits and HPV Vaccine Vaccination Rate 
Provider visit is a health encounter that can occur in acute settings or well visits, 
and these are opportunities for vaccination (Stokley et al., 2013). Stokley et al. (2013) 
argued that every health care visit is an opportunity to assess the immunization status of 
adolescents and to make recommendation for vaccine. After the approval of the HPV 
vaccine in 2006, the proportion of females unvaccinated from 2007 to 2012 rose from 
20.8% to 84.0% respectively (Stokley et al., 2013). Missed opportunities were noted for 
HPV vaccination, which, if eliminated, could have increased coverage with ≥1 dose to 
92.6 % (Stokley et al., .2013). According to Stokley et al., a missed opportunity was a 
clinical encounter with the provider that occurred on or after a girl's 11th birthday, when 
at least one dose of a vaccine was received, except the HPV vaccine. In the United States, 
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the high rate of HPV vaccination was not achieved yet because of the missed clinical 
opportunities (National Cancer Institute, n.d.). 
The 2012–2013 annual report by the President’s cancer panel identified failure to 
vaccinate at every clinical encounter as the most common reason why the United States 
has not attained optimal HPV vaccine uptake (National Cancer Institute, n.d.). Many 
adolescents eligible for vaccine did not get HPV vaccines at the time of providers' visits 
(National Cancer Institute, n.d.). Often, adolescents were vaccinated with other 
recommended vaccines on visiting their providers but failed to receive the HPV vaccine 
(National Cancer Institute, n.d.). Stokley et al. (2013) indicated that using every 
opportunity adolescents have with an health care encounter to assess vaccination status 
and vaccinate could limit missed opportunities. 
The 2014 NIS-Teen vaccination coverage among teens aged 13–17 years showed 
≥1 Tdap was 86.1% for Georgia, while being 87.6% for the United States (CDC, 2015). 
Compared to Tdap, the ≥1 dose HPV for adolescent females in Georgia was 65.4%, while 
nationally it was 60.0% (CDC, 2015). HPV≥2 doses and ≥3 doses for this group for 2014 
was 56.3% and 47.1% respectively (CDC, 2015). The data depicted missed opportunities 
for HPV vaccination, as the ≥1 Tdap was more than 20% greater than the ≥1 dose HPV 
(CDC, 2015). Also, ≥1 HPV vaccine dose uptake was lower than the Tdap and 
MenACWY rate in 2015, including previous years (Reagan-Steiner et al., 2016). Tdap 
and MenACWY were two vaccines regularly recommended at ages 11–12 years 
(Reagan-Steiner et al., 2016). The gaps observed in coverage revealed continued missed 
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chances for HPV vaccination during provider visits when other vaccines were given 
(Reagan-Steiner et al., 2016).   
Vadaparampil and Perkins (2014) noted that the United States had a low usage 
rate of the HPV vaccine compared to the other industrialized nations. Vadaparampil and 
Perkins observed that, although preventive care settings provide a basis for provider 
recommendation and vaccine usage, only 38% of adolescents had preventive visits. 
Physicians cited infrequent preventive health care visits as a barrier to vaccination 
(Stokley et al., 2013). However, nonpreventive care visits increase throughout the 
adolescence period from ages 11-17.8 years, expanding opportunities for 
recommendation of vaccine and coverage (Vadaparampil & Perkins, 2014). Adoption of 
provider practices to use acute or problem visits to initiate and provide catch-up 
vaccinations has the potential to increase the uptake of the HPV vaccine (Vadaparampil 
& Perkins, 2014). Using systems such as electronic health records that support efficient 
review of patients' records and can automatically flag patients not up-to-date for a HPV 
vaccination could facilitate this effort (Vadaparampil & Perkins, 2014). The timeline 
recommended for HPV vaccination corresponds to the vaccination series for Tdap and 
MCV4, and starting the HPV vaccine series during these visits could enhance the 
opportunities for improving vaccine coverage (Gable, Eder, Noonan, & Feemster, 2016). 
Gable et al. (2016) suggested that the administration of HPV vaccine during sick and well 
visits would minimize missed chances of vaccination.  
Taking advantage of every health care encounter or provider visit provides 
opportunities for provider recommendation of the HPV vaccine. Provider 
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recommendation was identified as influencing the HPV vaccination during provider visits 
(Ylitalo, Lee, & Mehta, 2013). Ylitalo et al. (2013) showed that adolescents with 
physician recommendation were often more likely to receive a vaccine (odds ratio = 
4.81).  
Data from the 2007–2012 NIS-Teen depicted increased missed opportunities for 
the HPV vaccination while there was higher coverage of other vaccines recommended for 
adolescents within the same period (Stokley et al., 2013). In addition, 84% of 
unvaccinated girls had provider visits where another vaccine was given (Stokley et al., 
2013). If the HPV 3 dose series were started at these visits, the use for ≥1 dose could 
have risen to 92.6% (Stokley et al., 2013). Also, enhancing the use of the HPV vaccine is 
possible with the current infrastructure and health care use in the United States (Stokley 
et al.,2013). 
Providers who service privately insured patients pay for their supply of vaccines 
out-of-pocket, including the cost of storing and administering vaccines (Gable et al., 
2016). Gable et al. (2016) noted that the cost incurred by providers could be a 
disincentive to recommend or store a vaccine. Also, some of the grandfathered health 
plans have inadequate coverage and create a financial barrier to this population (Gable et 
al., 2016). However, the ACA aids in increasing access to vaccinations for underinsured 
children eligible for VFC vaccines in the CHCs (Curtis et al., 2014; Forsberg et al., 
2014). 
In order to identify measures that would enhance the HPV vaccine uptake, Farmar 
et al. (2016) evaluated measures, such as bundling of vaccines, offering vaccines at every 
54 
 
visit, and use of standard orders implemented at Denver Health, an integrated urban 
safety net health system. The study was conducted from 2004 to 2014 among 11,463 
adolescents. In 2013, Farmar et al. showed that HPV coverage of ≥1 dose was 89.8% for 
female adolescents aged 13 to 17 years, compared to the national rate of 57.3%. Also, the 
rates of HPV vaccine coverage (≥3 doses) were 66.0% versus 37.6% nationally for the 
sampled population (Farmar et al., 2016). Bundling of vaccines during each provider visit 
minimized missed opportunities, which led to a higher vaccination rate in this health 
clinic (Farmar et al., 2016). 
Race / Ethnicity and HPV Vaccination Rate 
Race and ethnicity are used to characterize populations or groups based on shared 
features (Caprio et al., 2008). Race is used to classify populations based on biological 
traits like genes and skin color, while ethnicity is used to group people based on cultural 
characteristics, such as shared ancestry and language (Caprio et al., 2008).  
In the United States, adolescents made up 13.2% of the population, which was 
about 42 million in 2014 (Department of Health & Human Services [HHS], 2016). It is 
projected that this age group will increase to 45 million by 2050 (HHS, 2016). The 
adolescents vary by race and ethnicity reflecting a diverse population with differed 
socioeconomic status (HHS, 2016). As of 2014, 54% of adolescents are European 
American, and this group's population was projected to drop to 40% by 2050 (HHS, 
2016). Hispanic Americans and multiracial teenagers will become a larger population of 
teens while racial and ethnic minorities are predicted to increase (HHS, 2016).  
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Racial minorities are noted to have less access to health care, experience more 
severe health conditions, and have higher mortality rates than European Americans 
(HHS, 2016). People of color are at a higher risk of being uninsured than European 
Americans (KFF, 2016). The disparity in insurance coverage is higher for Hispanic 
Americans, who account for 20% of the nonelderly population but nearly a third (32%) of 
the nonelderly uninsured population (KFF, 2016). Hispanic Americans and African 
Americans have significantly higher uninsured rates (17.2% and 12.2%, respectively) 
than European Americans (8.1%; KFF, 2016). Health equity among the diverse 
adolescent population will be difficult to achieve if racial and ethnic disparities are not 
addressed (HHS, 2016).  
Differences exist in the risk for HPV-related infections and cervical cancers 
among races (HHS, 2016). Based on the Youth Risk Behavior for 2011, 60% of African 
American teens reported engaging in sexual intercourse compared to 48.6% of Hispanic 
Americans and 44.3% of European American teens (Jeudin et al., 2013). In addition, 14% 
of African American adolescents had first sexual intercourse before the age of13, 
compared to 7.1% for Hispanic Americans and 3.9% for European Americans (Jeudin et 
al., 2013). Also, 24.8% of African American teens reported having four or more lifetime 
partners, compared to 14.8% of Hispanic Americans and 13.1% of European Americans 
(Jeudin et al., 2013). The data reported a depicted increased risk and predisposition to 
HPV-related infections and cancers. Cervical cancer is the third most frequent cancer in 
the United States, with an estimated incidence of about 1,200 new cases and 4,000 deaths 
annually (Jeudin et al., 2013). The rate of cervical cancer was 53% and 41% higher 
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respectively for African Americans and Hispanic Americans compared to European 
Americans (Jeudin et al., 2013). There is a need to improve the HPV vaccination rate 
with a focus on the high-risk populations to prevent cervical cancer disparities (Jeudin et 
al., 2013).  
Among adolescents, more than 40% of the population live in poverty (KFF, 
2011). African American and Hispanic American teens are mostly affected (KFF, 2011). 
The adolescents who are of low income lack financial resources (KFF, 2011). Financial 
concerns or cost (if the vaccine is not free or the teen is uninsured) are barriers to 
providing the HPV vaccine (Emberger, 2015; Holman et al., 2014). A provision of the 
ACA was the expansion of Medicaid for individuals with incomes below 138% of FPL 
(Forsberg et al., 2014). About 22% of new Medicaid and CHIP recipients would be 
children if every state in the United States expanded Medicaid (Forsberg et al., 2014). 
Georgia was one of the states that opted out from expanding Medicaid and establishing a 
health market. The potential of limiting access to preventive services among adolescents 
of varied race, African Americans, and Hispanic Americans could hinder the HPV uptake 
(KFF, 2011). 
Scholars who have examined the HPV vaccination rate based on race/ethnicity 
observed differences in access (Forsberg et al., 2014). Cook et al. (as cited in Forsberg et 
al., 2014) identified Hispanic Americans are more likely to initiate the HPV vaccine. On 
the contrary, European American teens are most likely to complete the three-vaccine 
series (Forsberg et al., 2014). Jeudin, Liveright, Del Carmen, and Perkins (2014) found 
that low-income and minority adolescents are more likely to start the HPV vaccination 
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series than European American and higher-income adolescents, but are less likely to 
complete the series.   
The variation in the rate of the HPV vaccination might result from the pattern of 
provider recommendation. Ylitalo et al. (2013) examined the provider-verified HPV 
vaccination (≥ 1 dose) and participant-reported health care provider recommendation for 
the HPV vaccine. Ylitalo et al. revealed that adolescents were five times more likely to 
receive the vaccine if recommended by the provider (odds ratio = 4.81; 95% confidence 
interval = 4.01, 5.77). Ylitalo et al. showed that provider recommendation was less likely 
among racial/ethnic minorities, which denoted an association between recommendation 
and vaccination for all racial/ethnic groups. Limited access and health disparities can 
result in low patient engagement with health providers and subsequent underuse of health 
services (Washington, 2014). Low patient engagement with health providers resulted 
from limited access can impact the pattern of physician recommendation for the HPV 
vaccine.  
Race has an impact on the use of health services, and disparities in outcome exist 
across racial or ethnic groups (Healthy People, 2017). Poor health outcomes are observed 
among adolescents who are living in poverty, who are African American, American 
Indian, and or Hispanic American origin (Healthy People, 2017). In the United States, 
African Americans and Hispanic Americans are less likely to be insured than European 
Americans (Agency for Healthcare Research and Quality, 2016). However, the gap in 
insurance coverage decreased between 2010-2015 (Agency for Healthcare Research and 
Quality, 2016).  
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There is a relationship between race and ethnicity and the HPV vaccine use (Cates 
et al., 2010; Niccolai, Mehta, & Hadler, 2011; Wisk, Allchin, & Witt, 2014;). Cates et al. 
(2010) showed about 91% of parents reported having heard of the HPV vaccine, but non-
Hispanic, African American, or other races/ethnicities than non-Hispanic White are less 
likely to be aware of the HPV vaccine. Awareness was higher among parents with higher 
income (Cates et al., 2010). Wisk et al. (2014) examined 5,735 parents of preadolescents 
and adolescents from ages 8 to 17 years with data obtained from the 2010 National 
Health Interview Survey. Wisk et al. revealed that 62.6% of parents were aware of the 
HPV vaccines. However, European American parents with older children, English 
speaking, who were married, more educated, and with higher incomes above 200% of the 
FPL and living in the Midwest were more aware of the vaccine (Wisk et al., 2014). Not 
expanding Medicaid under the ACA in Georgia is a potential barrier to having access to 
the health care provider. In addition, a lack of access to preventive services will prevent 
the imparting of knowledge of the HPV vaccine and recommendation from a health 
provider. For health information to be useful and beneficial, it must be accessible, 
understandable, accurate, and timely (Washington, 2014).  
People with higher education and income are predisposed to having access to 
health resources and engaging in preventive health actions (Feinberg et al., 2016). 
However, individuals with low income, low educational level, and a lack of English 
proficiency are prone to having low literacy (Feinberg et al., 2016). These individuals are 
likely to be African American, Hispanic American, and Native American (Feinberg et al., 
2016). A lack of access or insurance coverage can impede the seeking of health 
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information and contact with a health provider, unlike those who have insurance 
(Feinberg et al., 2016).  
Niccolai et al. (2011) assessed the effects of race/ethnicity, poverty, and year 
completion of the three-dose HPV vaccine series among those who initiated vaccination. 
This study was conducted among adolescent females, ages 13 to 17 years, using data 
from the 2008-2009 NIS-Teen. The sampled population was (n=7606), and analysis was 
done with logistic regression to adjust for covariates and measures of access to care from 
2010-2011 (Niccolai et al., 2011). Niccolai et al. revealed that 55% of adolescent girls 
completed the three series, but on controlling covariates, variation existed based on race. 
African American (AOR=0.48, 95% CI=0.40, 0.57) or Hispanic American (AOR=0.75, 
95% CI=0.64, 0.88) were significantly less likely to complete vaccination than European 
Americans (Niccolai et al., 2011). 
The patterns of HPV vaccine uptake were evaluated by race/ethnicity and poverty 
status using the NIS-Teen data from 2008 -2011 (Bednarczyk, Curran, Orenstein, & 
Omer, 2017). Bednarczyk et al. (2017) showed that Hispanic American adolescent 
females had the highest initiation rate of HPV vaccine (44.4%), followed by African 
Americans, while the European American adolescents had the lowest uptake. Also, the 
Hispanic American adolescent females’ average increase in HPV vaccine uptake was 
almost twice more than the European Americans (7.0% vs 3.8%; Bednarczyk et al., 
2017). 
About 20,589 cases cancers associated with HPV are diagnosed among females 
annually in the United States (Henry, Stroup, Warner, & Kepka, 2016). These cancers are 
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preventable if the HPV vaccine is initiated before first sexual intercourse. Risk of 
exposure to HPV-related infections and subsequent cancers in adulthood is prevalent 
among adolescents, which result in sexual risk behaviors. The variation in risks and 
exposure is common among African Americans, Hispanic Americans, and minorities, 
which depicts race/ethnicity being significant in exposure. Understanding the role of 
race/ethnicity predisposition to the risk of HPV-related infections and cancers, including 
socioeconomic factors that hinder HPV vaccine uptake, will guide in developing 
strategies that will enhance the use of the HPV vaccine among adolescent females in 
Georgia. It is necessary to improve the HPV vaccine use as this population is projected to 
continually grow (Jeudin et al., 2014). 
Several of the ACA provisions provided opportunities to increase access and 
quality of preventive services, such as no cost-sharing for adolescents (Forsberg et al., 
2014). The ACA also provided funding for CHS, SBHCs, and local health departments to 
expand and support the infrastructure through which preventive and health care services 
are offered (Forsberg et al., 2014). All of these provisions have the potential of improving 
access to a health care provider resulting in health care encounter or visits. Stokley et al. 
(2013) reported that 84% of adolescent females who had health care encounters or visits 
in 2012 based on NIS-Teen data did not receive HPV vaccine, while other vaccines were 
given. Although the ACA provided access and infrastructure, the HPV use rate remains 
low in Georgia. The focus of this study was on monitoring the trend of HPV vaccination 
from 2011 to 2015 by exploring if ACA influenced use or coverage. 
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Conclusion 
In Chapter 2, I presented a literature review on ACA and use of the HPV vaccine 
among adolescent females in Georgia. HPV is associated with latent infections that could 
cause genital warts and cervical and oropharyngeal cancers in adulthood (CDC, 2015; 
Dunne et al., 2014; Stokely et al. 2013). Infections caused by HPV could cause cervical, 
vaginal, and vulvar cancers in women; oropharyngeal and anal cancers, including genital 
warts in both males and females; and penile cancers in men (Meites et al., 2016).  
 Georgia's prevailing rate of cervical and oropharyngeal cancers linked to HPV is 
above the national average of 7.7% and 12.1% respectively (Berzen et al., 2016). The 
ACA, enacted in 2010, aimed to increase access to HPV vaccine. The HPV vaccine is 
effective in preventing latent infections that result in various cancers if administered early 
among teens before initiation of sexual activity. Despite the implementation of this law, 
the rate of the HPV vaccine use is below the Healthy People 2020 goal for adolescents in 
Georgia. Scholars who have examined why the underuse exists focused on parental 
knowledge, attitude, and provider recommendations, but none examined if the ACA 
influenced use as private insurance and uninsured with cost-sharing. This was the gap this 
study filled.  
The knowledge obtained from this study will improve understanding on why the 
underuse of the HPV vaccine still exists. Examining the trend in vaccinations from 2011 
to 2015 helped in deducing if there was association. Measuring the relationship aided in 
portraying the level of significance of access in the use of the HPV vaccine among 
adolescents in Georgia. I conducted logistic regression analysis of the variables within 
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the periods chosen to determine association and trend. Given the high prevalence of 
HPV-related infections and cancers in Georgia, it was vital to understand that this is a 
public health problem. Being able to ascertain if the ACA impacted the use of the HPV 
vaccine and the most significant factor that influenced the use of the vaccine helped in 
filling the gap in the existing literature relating to HPV vaccine use and insurance 
coverage.  
In Chapter 3, I will provide the details of the study, research design, and the 
rationale. I will present a description of the methodology; population; sampling and 
sampling procedures; recruitment; data collection; permissions to gain access; 
operationalization; and independent, dependent, and covariate variables. Also, this 
chapter includes the literature search strategy, inclusion and exclusion criteria for studies 
and data analysis plan, ethical procedures, summary, and transition to Chapter 4. 
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Chapter 3: Research Method 
Introduction 
HPV is the main cause of STDs in the United States (Dunne et al., 2014; National 
Cancer Institute, 2015; Sun et al., 2013). The infection is found mostly among youths 
ages 15 to 24 years, who acquire 50% of the 20 million new STDs annually (CDC, 2015). 
Also, one in four sexually active adolescent girls has an STD, such as HPV (CDC, 2015). 
Despite the prevalence of HPV-related STDs among adolescent females, underuse of the 
HPV vaccine, proven to be effective in preventing the infection, still exists, especially in 
Georgia. Scholars have not examined if insurance coverage under the ACA influenced 
the use of the vaccine, as adolescents with private insurance and the uninsured had 
increased odds of vaccination. Given the increased prevalence of HPV-related infections 
among adolescent females in the United States and the underuse of the HPV vaccine 
among teenage females in Georgia, determining the degree of association between the 
ACA and HPV vaccine use will depict the scope and gravity of the problem. The purpose 
of this study was to explore the association between the ACA and HPV vaccine use 
among adolescent females in Georgia. The population sample was small, as the focus was 
only on Georgia. However, observing the trend of vaccination for multiple years after the 
enactment of ACA and analyzing the results helped in providing knowledge on this issue 
at the state level. 
The first section of Chapter 3 consists of the research design and rationale. The 
research questions are restated, and I provide an explanation for the use of secondary data 
analysis of the quantitative survey design. Subsequently, the research sample, process of 
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selecting the sample and the variables, and the procedures for data collection associated 
with the study is discussed. Also, data analysis, threats to validity, and a summary of this 
chapter are described. 
Research Questions and Hypotheses 
RQ1: Is there any association between ACA with no cost-sharing and the HPV 
vaccination rate among adolescent females in Georgia? 
H01: There is no association between ACA with no-cost sharing and the HPV 
vaccination rate among adolescent females in Georgia. 
Ha1: There is a significant association between ACA with no cost-sharing and the 
HPV vaccination rate among adolescent females in Georgia. 
RQ2: Is there any association between ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia? 
H02: There is no association between ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia. 
Ha2: There is an association between the ACA with no cost-sharing and the rate 
of provider visit among adolescent females in Georgia.  
RQ3: Is there any association between provider visits and the HPV vaccination 
rate among adolescent females in Georgia? 
H03: There is no association between the provider visits and the HPV vaccination 
rate among adolescent females in Georgia. 
Ha3: There is an association between the provider visits and the HPV vaccine 
vaccination rate among adolescent females. 
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RQ4: As Georgia did not expand Medicaid under ACA, is there any association 
between race and the HPV vaccination rate among adolescent females in Georgia? 
H04: There is no association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
Ha4: There is an association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
Research Design and Rationale 
This research was a secondary data analysis of the U.S. NIS-Teen data from 2011 
–2015. The NIS-Teen is a nationally representative, annual survey of adolescents aged 
13-17 years living in noninstitutionalized households in the United States, sponsored by 
the CDC (2015). The NIS-Teen used a random digit dialing telephone survey of 
households screened for the presence of 13-to 17-year-old adolescents. In 2015, both 
landline and cellular phone surveys were done. An interview was conducted with an adult 
who was most knowledgeable about the adolescent’s immunization history (Reagan-
Steiner et al., 2016). The NIS-Teen also collects information on vaccinations from the 
teens’ health care provider by mailing the questionnaire. The survey ensures comparable 
vaccination coverage levels within estimation areas at all times due to the use of the same 
methodology in data collection and survey instruments (Reagan-Steiner et al., 2016). 
Samples of telephone numbers are drawn independently for each calendar quarter, within 
selected geographical areas or strata (CDC, 2015). This design enables the annual 
estimates of vaccination coverage levels for each state or territory (CDC, 2015). The data 
collected from the 2011–2015 NIS-Teen survey had an average response rate of 58.7%. 
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In this secondary data analysis, I employed a quantitative design to analyze data 
pertaining these variables: health insurance (ACA; independent variable), HPV 
vaccination rate (dependent variable), race (moderator variable), and provider visit as the 
mediating variable.  
I chose this design to statistically quantify if there was an association between the 
ACA and the HPV vaccination rate among teenage females and to provide insight into 
the magnitude of relationship and the problem in Georgia. Also, secondary data analysis 
is cost-effective, as I did not have the resources to collect the needed data with rigor in a 
timely manner. The NIS is conducted by the National Opinion Research Center (NORC), 
staffed with skilled professionals, such as epidemiologists, statisticians, and health 
scientists, who ensured rigor through the instrumentation to minimize the threat to both 
external and internal validity. 
Definition of Key Study Variables 
HPV testing history was defined using the question “Has teen ever received any 
human papillomavirus shots?” Responses of yes were defined as having received an HPV 
vaccination, while no responses were defined as having never been vaccinated for HPV. 
Health insurance coverage was assessed by whether there were gaps in health insurance 
coverage since age 11 (yes and no). 
Demographic and health-related covariates included race. Other variables related 
to provider visits included whether the teen visited the doctor in the past 12 months (yes 
or no; CDC, 2015). 
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This study was a secondary analysis of data with no attempt to control or 
manipulate the variables. The analysis was conducted on the NIS-Teen data from 2011–
2015 using questions derived from data that applied to Andersen's (1974) BM of health 
care use constructs. In the BM, Anderson postulated three factors that result in the use of 
health services: predisposing, enabling, and need factors. The questions derived were 
pertinent to the predisposing factors consisting of (race/ethnicity); enabling factors 
(access to health insurance coverage [ACA]); and provider visits (regular source of care) 
perceived need (HPV vaccine). The questions on these variables can be recognized from 
the categorization of data based on survey questions from the NIS from 2011–2015. The 
weights included in this public use data file permit the conducting of several different 
types of analysis, depending on interests and aims (CDC, 2017). 
The purpose of this study was to determine if the ACA as the independent 
(predictor) variable had any association with the HPV vaccination rate (dependent 
variable) among adolescent females in Georgia. This relationship was ascertained by 
exploring the factors that impacted access to health care and use through secondary 
analysis of data obtained from the NIS from 2011–2015. Also, I analyzed race and 
provider visits as covariate variables that could influence relationship. The quantitative 
design was the appropriate methodology for this research, as I tested the hypotheses using 
quantitative data. I determine if there was any association, and the degree of association, 
between the independent and dependent variable from 2011–2015. Using data from 
multiple years, primarily collected by the National Center for Health Statistics (NCHS) 
and CDC, provided a more convincing evidence than a single-year data analysis. 
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Population 
The data used for this study were obtained from the NIS-Teen from 2011 to 2015. 
The NIS-Teen survey is conducted nationally and annually among adolescents ages 13-
17 years living in noninstitutionalized households in the United States (CDC, 2015). The 
purpose is to monitor the progress of vaccination coverage toward achieving the 
objectives of the Childhood Immunization Initiative (CDC, 2015). The analytical sample 
was only on female teens aged 13-17 residing in the state of Georgia at the period before 
the interview (N =1,500). The unweighted sample size for analysis was 1,500, 
representing an estimated 303,920 girls ages 13 to 17 living in Georgia from 2011 to 
2015. 
I used the effect size for the analysis to measure the increases in the annual 
prevalence of girls ages 13 to 17 living in Georgia who reported ever receiving any HPV 
shots. The prevalence rate from 2011 to 2015 was 36.5%; in 2011, it was 40.3%; in 2012, 
it was 53.5%; in 2013, it was 58.6%; and in 2014 and 2015, it was 46.7%. Prevalence 
increased significantly at P value < 0.0002. 
Power Analysis 
Statistically, a power analysis was performed for sample size estimation, based on 
data from the 2011-2015 NIS. The purpose of the study was to assess the rate of HPV 
vaccinations among teenaged girls ages 13-17 living in Georgia and whether the rate 
increased after the enactment of the ACA from 2011-2015. The total sample size for 
survey respondents was 1,500. The effect size was calculated by assessing the percentage 
of teenage girls who reported being vaccinated for HPV as opposed to the rate of girls 
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who reported never receiving the vaccination (47.0%-yes; 53.1%-no). The p-value was 
derived using the chi-square statistic and was significant at p = (0.0002), thus warranting 
the subsequent power analysis. 
With an alpha=.05 and power=0.80, the projected sample size needed with this 
effect size was approximately 710 with at least 142 respondents for every year of survey 
data. The sample size was 1,500 (included 330 [2011]; 240 [2012]; 220 [2013]; 332 
[2014]; and 378 [2015]). The sample size was more than adequate for the primary 
objective of this study. Also, it allowed for expected attrition and the additional 
objectives of controlling for possible mediating, moderating factors, and subgroup 
analysis. 
Procedures for Recruitment, Participation, and Data Collection 
The NIS-Teen used a survey methodology that involved a random digit dialing 
telephone to identify households to screen for the presence of 13-to 17-year-old 
adolescents. From 2011, both landline and cellular phone surveys were implemented due 
to increased usage of cell phones by most households (CDC, 2014). Samples of telephone 
numbers were selected randomly every quarter, in chosen geographical areas or strata 
(CDC, 2014). This design allowed for a rough calculation of the level of vaccination 
coverage for every state or territory annually (CDC, 2014). The process involved 
interviewing an adult who was most knowledgeable about the adolescent’s immunization 
history (CDC, 2014). Only a teen is randomly chosen for the interview in each household 
(CDC, 2014).   
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Upon completion of the phone interview, consent was obtained from the teen's 
parent or guardian to contact the child's health care providers (CDC, 2014). After, the 
NIS contacted the health care provider(s) of the teen to request information on 
vaccinations from the age 11 years by mail (CDC, 2014). The request helped in 
determining the rate of provider visits. Using the same data collection methodology and 
survey instruments, the NIS produced comparable vaccination coverage levels within the 
estimation areas over a period. Data collected from the 2011–2015 NIS-Teen had an 
average response rate of 58.7%. The analytical sample was restricted to female teens 
aged 13-17 residing in the state of Georgia at the time before the interview (N = 1,500). 
Procedures for Gaining Access to the Data Set 
The dataset used for this study was the NIS-Teen data. These data were open to 
the public and can be accessed from its home page located at 
https://www.cdc.gov/vaccines/imz-managers/nis/index.html. The NIS public use data file 
was available in ASCII format. An SAS program (in ASCII format) facilitated the 
reading of the ASCII data file and in creating an SAS data set. The data were 
downloaded, and an SAS program was used to convert the data from an ASCII file to an 
Excel spreadsheet. 
Permission to Gain Access to the Data 
Permission was sought by sending an e-mail to cdcinfo@cdc.gov. Public Health 
Service Act (Section 308(d) stipulated that the data collected by the CDC (2015) may be 
used only for health statistical reporting and analysis.  
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CDC info responded to the e-mail request and indicated no permission was 
required to use the data. The response from CDC info is attached to Appendix B. I 
conducted a health statistical reporting and analysis of a selected portion of these 
archived data that focused on insurance coverage (ACA), HPV vaccination, social 
demographic (age and sex), and health care provider visits. Health statistical analysis 
complied with the Public Health Service Act (Section 308(d). 
Instrumentation 
The instruments used for the survey were questionnaires that were in two forms 
(household RDD telephone survey [Computer-Assisted Telephone Interview 
questionnaire] instrument in both English and Spanish for households) and a mail survey 
of vaccination providers, known as the Immunization History Questionnaire (IHQ) 
(CDC, 2017). The NIS Teen survey was included in the NIS for childhood immunization 
in the fourth quarters of 2006 and 2007 (CDC, 2017). The CDC (200) designed the NIS. 
These researchers evaluated various survey methodologies that could provide uniform 
measures in monitoring vaccination coverage levels for states and urban areas in the 
United States (Zell, Ezzati-Rice, Battaglia, & Wright, 2000). Finally, a RDD telephone 
survey with a provider record-check study was selected as the best option for the survey 
(Smith et al., 2001; Zell et al., 2000).  
The NIS Teen survey was conducted within 58 estimation areas, where landline 
telephone and cell phone numbers were sampled within estimation areas in each quarter 
(CDC, 2014). The method involved selecting a random sample of telephone numbers 
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from banks of 100 consecutive phone numbers, which were reviewed and updated every 
quarter (CDC, 2014). 
The design and implementation of the NIS-Teen landline sample involved four 
procedures that used statistical models to predict the number of sample telephone 
numbers needed in each estimation area to meet the target precision requirements (CDC, 
2014). The sample selected was randomly divided into strata after eliminating 
nonworking and nonresidential phone numbers through an automated procedure (CDC, 
2014). The sampled phone numbers were matched against a national database of 
residential landline phone numbers (CDC, 2014). Also, 2 weeks before the household 
interview, a letter was sent to identifiable mailing addresses (CDC, 2014). The surveys 
were supported and conducted by the CDC (2017) and were authorized by the Public 
Health Service Act. Currently, the NIS are conducted by the NORC at the University of 
Chicago (CDC, 2017). 
For the provider mail questionnaire, a focus group was conducted in 2009 among 
physicians, nurses, and other nonphysician office staff (DeMaio & Beck, 2009). The aim 
of assembling a focus group was to comprehend how health care providers would 
respond to the mailing materials (DeMaio & Beck, 2009). The feedback obtained from 
this process was incorporated into the provider materials to simplify it (DeMaio & Beck, 
2009). 
Record checks are done before mailing packets to providers, during a telephone 
call, editing of returned questionnaires, and during and after data entry (CDC, 2014). 
During the processing of the returned questionnaires or vaccination records, all records 
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were examined to look for errors, and corrections were made prior to data entry with a 
subsequent 100% verification (CDC, 2014). The error rate was estimated, through second 
verification process, to be less than 1% (CDC, 2014). 
Further, the data were edited and cleaned through the CATI system, which 
enabled reconciliation of potential mistakes while the respondent was still on the 
telephone (CDC, 2014). More editing and cleaning of data were done post-CATI clean-
up stage. The process involved a review of data values, cross tabulations, and the 
recoding of responses for race and ethnicity, including the creation of numerous 
composite variables (CDC, 2014). 
Finally, to assess the validity of estimates of vaccine coverage from the NIS, the 
1995 and 1996 NIS national vaccine estimates were compared with results from the 
NHIS/NIPRCS for the same years (Bartlett, Ezzati-Rice, Stokley, & Zhao, 2001). Both 
the NIS and the NHIS/NIPRCS produced similar results, confirming the validity of the 
instrument (Bartlett et al., 2001).  
Operationalization 
This study involved conducting a secondary analysis using only a portion of the 
questionnaires that were applicable from a more extensive NIS-Teen database. The 
survey questions selected for review were operationalized to apply to the constructs of 
Andersen's (1974) BM. The applicable survey questions are found in Appendix A. 
Measures 
A secondary analysis of data from the NIS-Teen survey database was tested to 
determine if ACA insurance coverage with no cost-sharing for preventive health services 
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had an impact on the use of the HPV vaccine among adolescent females, ages 13 to 17 
years, living in Georgia. The NIS-Teen routinely surveyed a large population of teens to 
ascertain the level of vaccination coverage, based on stratification and IAP areas. 
Information about receipt of the vaccine was obtained from the parent who was most 
knowledgeable about the teen’s immunization and provider record check. The secondary 
analysis included only girls, ages 13 to 17, living in Georgia who reported ever receiving 
any HPV shots from 2011 to 2015. The sample size for the study was 1,500, representing 
an estimated 303,920 girls, ages 13 to 17, living in Georgia from 2011 to 2015, extracted 
from the NIS database.   
The NIS-Teen survey monitored various trends that included constructs selected 
for inclusion in this study. The constructs aligned with the three factors that influence the 
use of health services based on Andersen's (1974) BM. The constructs are predisposing 
factors (race/ethnicity), enabling factor (health insurance coverage and provider visit), 
and perceived need (HPV vaccine). The details of each construct, questions, and 
responses are discussed.  
Predisposing Factors for Race/Ethnicity 
Predisposing factors are used to explain the inclination to use health services by 
individuals, and use occurs when a person is predisposed to receive health services, such 
as the HPV vaccine, to prevent the risks of contracting HPV-related diseases and cancers. 
These were represented by NIS Teen survey questions from 2011 to 2015: 
• “Is [TEEN] White, Black or African American, American Indian, Alaska 
Native, Asian, Native Hawaiian or other Pacific Islander”? 
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These were demographic- and health-related covariates (race). The responses to race for 
multiple years 2011–2015 helped to generate prevalence estimates of the HPV 
vaccination history of teenage girls, aged 13-17, living in the state of Georgia from 2011 
to 2015 using the SAS-Callable SUDAAN software. I used the responses to determine if 
race had an influence on the rate of the HPV vaccine. The response to this question 
helped in answering the RQ4: As Georgia did not expand Medicaid under ACA, is there 
any association between race and the HPV vaccination rate among adolescent females in 
Georgia? 
Enabling Factors for Health Insurance Coverage (ACA) 
These were conditions that enhance or facilitate the use of health services, such as 
access to health insurance coverage. The represented question from the NIS Teen survey 
was the following:  
• "Since age 11, any time when the teen was not covered by any health 
insurance?"  
This question was used to determine whether there were any gaps in health insurance 
coverage since age 11 (yes and no). I used the response to this question to answer RQ1: Is 
there any association between the ACA and the HPV vaccine vaccination rate among 
adolescent females in Georgia? 
Enabling Factors for Provider Visits 
I used the responses to the questions below to answer RQ2: Is there any 
association between insurance coverage under the ACA and the rate of provider visits 
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among adolescent females in Georgia? and RQ3: Is there any association between the 
rate of provider visit and the HPV vaccination rate among adolescent females in Georgia? 
• “What was the date of this child's most recent visit, for any reason, to this 
place of practice"?  
• "During the past 12 months, how many times has [TEEN] seen a doctor or 
other healthcare professional about [GENDER2] health at a doctor's 
office, a clinic, or some other place"? Answered (yes and no). 
The need for HPV vaccine prompted provider visit. Also, 100% coverage of preventive 
services, such as the HPV vaccine, led to increased access, which likely increased 
provider visits.  
Perceived Need for HPV Vaccine 
Perceived need is on a person’s view and experience on general health, functional 
state, and or illness that prompt the use of health services, such as the HPV vaccine. HPV 
vaccine testing history was defined using the questions listed below: 
• “Has [teen] ever received HPV shots”?  
• “How many HPV shots did [teen] ever receive”? 
Respondents who answered yes were defined as having received an HPV vaccination. 
Respondents who answered no were defined as having never been vaccinated for HPV. 
These questions helped to answer the RQ1: Is there any association between the ACA 
and the HPV vaccine vaccination rate among adolescent females in Georgia? 
No treatment intervention was involved in this study. I focused on the analysis of 
secondary data obtained from the NIS Teen database, based on a nonexperimental survey 
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of the randomly selected teen population nationwide. The analysis was limited to 
adolescent females living in Georgia from 2011–2015 after the enactment of the ACA. 
The trend of vaccination was compared across these years to ascertain if there was an 
association between ACA insurance coverage and the rate of HPV vaccine use among 
adolescent females in Georgia. 
Statistical Data Analysis 
SAS-Callable SUDAAN software (Release 10.0, Research Triangle Institute, and 
NC) was used to generate prevalence estimates of the HPV vaccination history of teenage 
girls aged 13-17 living in the state of Georgia from 2011 to 2015. All analyses accounted 
for the complex NIS-Teen survey design and data weights. Logistic regression analyses 
were used to calculate prevalence, prevalence ratios (PRs), and 95% confidence intervals 
(95% CIs) for each independent variable to assess the association with ever being 
vaccinated for HPV. The multivariable analyses were controlled for all significant study 
variables (p<0.05) to calculate the adjusted prevalence ratios (APRs). 
Assessment of Each Research Question 
The relationship between the dependent variable (HPV vaccination rate) and 
independent variable (ACA insurance) including covariates, such as provider visit and 
race, were evaluated. Logistic regression analyses were used to calculate prevalence, 
PRs, and 95% CIs for each independent variable to assess the association with ever being 
vaccinated for HPV. For the multivariable analyses, there was control for all significant 
study variables (p<0.05) to calculate the APRs. 
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Justification 
Logistic regression analyses were used to calculate prevalence, PRs and 95% CIs 
for each independent variable to assess the association with ever being vaccinated for 
HPV. For the multivariable analyses, there was a control for all significant study 
variables (p<0.05) to calculate the APRs. PRs based on multivariate regression models 
was used for the hypothesis testing to isolate the association between the outcome 
variable (i.e., the rate of insurance coverage) independent study variable from 
background characteristics of the study population. Also, PRs based on multivariate 
regression model was used in this analysis because it was recommended by the NCHS for 
the analysis of nationally representative data, which are available in the statistical 
software package. Multivariate regression is a standard statistical method that relates 
multiple independent variables to a single dependent variable. When used in conjunction 
with nationally representative data from the NIS, analytical results can be used to test the 
null hypothesis for each research question generalizable to the population of teenage girls 
ages 13 to 17 years living in the state of Georgia from 2011–2015. 
Logistic regression analysis models are employed when studying or estimating the 
relationship between a dependent variable with more than one independent variable 
(Schneider, Hommel, & Blettner, 2010; Uyanıka & Gülerb, 2013). For multiple 
regression analysis, the assumptions include (normality) variables must have normal 
distribution, (linearity) model should be linear, and(homoscedasticity) constant variance 
across the predicted variables level (Uyanıka & Gülerb, 2013). It was the appropriate 
model of analysis for this study because it allowed me to examine multiple independent 
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variables with adjustment of their regression coefficients for possible confounding effects 
between variables (Schneider et al., 2010). 
Threats to Validity 
As the research conducted was nonexperimental, there were threats to validity in 
the measurement. For internal validity, the threats may involve selection and 
measurement bias. The NIS was designed by researchers at the CDC (2000). The 
population surveyed were randomly selected. Quality control measures applied included 
the RDD component of the NIS-Teen and online provider lookups in the database system 
integrated with the CATI system, which included the names, addresses, and telephone 
numbers of vaccination providers (CDC, 2014). Also included was automated range-edits 
and consistency checks, which minimized the threat to internal validity. The external 
validity threat could result if the results of the study were generalized to the entire 
population of adolescent females living in Georgia. Another concern for this study was 
the construct validity. It was necessary to know if the questions asked in the NIS Teen 
Survey were valid and reliable to apply them to the constructs of Andersen's (1974) BM. 
The NIS Teen Survey questions were constructed to be reliable and valid through 
various processes (CDC, 2000) that included 
• The NIS Teen survey was added to the NIS for childhood immunization in 
the 4th quarters of 2006 and 2007 (CDC, 2017; Jain, Singleton, 
Montgomery, & Skalland, 2009). 
• The NIS was designed by researchers at the CDC (2000). 
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• These researchers evaluated various survey methodologies before deciding 
on inclusion and exclusion criteria. 
• Scientific validity was the basis for inclusion items in the two forms of 
questionnaires (household RDD telephone survey CATI instrument) in 
both English and Spanish for households and a mail survey of vaccination 
providers (IHQ). 
• The inclusion items in both forms of questionnaires demonstrated 
measurement of population-based constructs in reliable ways and were 
supported by external evidence that showed the suitability of the 
measures.  
• Pretesting was conducted followed by expert reviews. 
• NORC administers the NIS. 
• A random sample of both landline and cellphone numbers from banks of 
100 consecutive telephone numbers within 58 estimation areas, which 
were reviewed and updated, every quarter was applied. 
• In each estimation area, the target sample size of completed telephone 
interviews was designed to achieve an approximately equal coefficient of 
variation of 6.5%, an estimate of vaccination coverage derived from 
provider-reported vaccination histories, for an actual coverage parameter 
of 50%.  
• Both landline and cellphone sample sizes were selected, so when 
combined would meet the target coefficient of variation of 6.5%. 
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• The above measures were taken to maximize response rate, including 
sending an introductory letter about the interview in advance to 
households and a telephone call to providers who did not respond, as a 
reminder to complete the form, then either mail or fax the information. 
For this study, the only inclusion criteria for participants were adults in the 
households with the most knowledge of the teen’s (13 years to 17 years) immunization 
history that responded to the NIS Teen Survey from 2001 to 2015. The potential for a 
slight error in the selection criteria could occur if an adult not knowledgeable answered 
the questions. However, the information obtained was matched with the providers' to 
minimize error. Data collected were edited, entered, cleaned, and merged with the 
household information from the RDD survey to produce a teen-level record (CDC, 2017). 
Also, the use of dual-frame weights estimates of both cell and landline phones helped in 
minimizing bias. 
Researchers in various periods after the inception of the NIS Teen survey 
categorized the questions of the survey with a focus on parental awareness (Wisk et al., 
2014). Further categorizations were from provider recommendation (Mohammed et al., 
2016) and geographical factors (Henry et al., 2016). However, I measured predisposing 
factor (race/ethnicity), enabling factors (ACA), and need factors (HPV vaccination rate 
and the rate of provider visit). All of the questions for these constructs were categorized 
under sociodemographic race (predisposing), insurance coverage (enabling), and HPV 
vaccination rate and provider visits (perceived need) in the NIS Teen database. The NIS 
Teen survey was validated to be reliable as it was an add-on to the NIS. The questions 
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and measurement instruments for the Teen survey was validated to be reliable based on 
the outcome of the study for both the NIS and the NHIS/NIPRCS that produced similar 
results.  
Ethical Procedures 
Permission to use the NIS Teen data from 2011 to 2015 was sought through the 
CDC-INFO. The first inquiry was made on July 26, 2017, followed up on August 1, 
2017. The response was received back on August 1, 2017 from CDC-INFO that 
permission was not required for the use of public domain items. Although the data were 
available for public use, CDC–INFO team members were aware that this research was 
being conducted. The letter was written, and the response was placed in Appendix B. 
Treatment of Human Subjects 
Human participants were not accessed, but the secondary data were collected 
during the NIS-Teen survey from 2011–2015. The data obtained were used just for health 
statistical reporting and analysis based on the Public Health Service Act (CDC, 2014). 
The NCHS ensured that the identity of data subjects was not disclosed by omitting direct 
identifiers and any characteristics that might lead to identification. No attempt was made 
to access any identifying information. The data were used only for health statistical 
reporting and analysis after the approval of the institutional review board (IRB) at 
Walden University. 
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Institutional Permissions 
The request for the study approval was submitted to the Walden University IRB 
before data collection. Approval was obtained from the Walden IRB before data 
collection. IRB approval number is 01-31-18-0123614. 
Ethical Concerns 
This study involved a secondary analysis of existing data. There was no contact 
with subjects, and no intervention activities were included. Approval was sought through 
Walden’s IRB before data collection.  
Treatment of Data 
The data were handled in a professional manner. Anonymity was maintained by 
the NCHS without any identifiable link. The notes and reports were worded 
professionally, indicating respect for the sampled population who responded to the 
survey.   
Summary 
This research was a quantitative study consisting of statistical analysis of 
secondary data from the NIS-Teen survey conducted from 2011–2015. The NIS-Teen 
database is a national database open to the public to use for statistical analysis. The 
purpose of this study was to explore if insurance coverage without cost-sharing for 
preventive services under the ACA influenced the use of the HPV vaccine among 
adolescent females in Georgia. The aim was to determine if there was relationship or 
association, and the level of the relationship, between the ACA and the HPV vaccination 
rate. The results of this study helped to fill the gap in the literature. The rate of HPV 
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vaccination was lower among teens in high school who faced out-of-pocket cost with 
private insurance. Cost incurred was the barrier observed that minimized the HPV 
vaccine use. Health care insurance reform without out-of-pocket expenses was 
recommended as a strategy that would increase the use of the HPV vaccine. None of the 
studies I reviewed examined if ACA with no-costing sharing (new health policy) had an 
impact on HPV vaccine use among adolescent females in Georgia. Andersen's (1974) 
BM was the conceptual framework that was applied for this research. 
In Chapter 3, I described the research study, research questions, hypotheses, and 
relevant issues related to secondary data analysis. Secondary analysis of existing data 
involved two methods: research question-driven and data-driven approaches (Cheng & 
Philips, 2014). For this research, both approaches were employed. The research questions 
were formed before searching suitable datasets that would address the research questions. 
Also, the variables in the NIS Teen dataset were looked at to decide the questions that 
could be answered by the available data. 
This chapter provided information on the target population and the effect size 
computation, sampling and sampling procedures for recruitment, participation and data 
collection, and method for gaining access to the data. Also, an explanation was given on 
the instrumentation and operationalization of constructs, data analysis plan, threats to 
validity, and ethical procedures. In Chapter 4, I will discuss the collection of data and 
results of the study. 
 
85 
 
Chapter 4: Results  
Introduction 
The primary focus of this secondary data quantitative study was to determine if 
there was an association between the ACA and the use rate of the HPV vaccine among 
adolescent females in Georgia. Also, I aimed to discover the most significant factor under 
Andersen's (1974) BM of health care use that influenced the use of the HPV vaccine. 
Given the prevalence of STDs and cancers associated with HPV, including the low rate 
of HPV vaccination among adolescent females in Georgia, it was necessary to create 
awareness of the level of the problem. Determining the degree of association between 
health care reforms (ACA) with no cost-sharing with the HPV vaccination rate among 
adolescent females in Georgia is the first step in developing strategies and interventions 
that can enhance the use of the HPV vaccine. Effective interventions will yield 
improvement in the HPV vaccination rate, which will result in the decrease in the rate of 
HPV-related STDs and cancers while increasing herd immunity. Four research questions 
were structured to determine the level of association between the ACA and the HPV 
vaccination rate among adolescent females. 
The four research questions and hypotheses involved in this study were 
RQ1: Is there any association between the ACA with no-cost sharing and the 
HPV vaccination rate among adolescent females in Georgia? 
H01: There is no association between the ACA with no cost-sharing and the HPV 
vaccination rate among adolescent females in Georgia.  
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Ha1: There is a significant association between the ACA with no-cost sharing and 
the HPV vaccination rate among adolescent females in Georgia. 
RQ2: Is there any association between the ACA with no-cost sharing and the rate 
of provider visit among adolescent females in Georgia? 
H02: There is no association between the ACA and the rate of provider visit 
among adolescent females in Georgia. 
Ha2: There is an association between the ACA and the rate of provider visit 
among adolescent females in Georgia.  
RQ3: Is there any association between provider visits and the HPV vaccination 
rate among adolescent females in Georgia? 
H03: There is no association between the provider visits and the HPV vaccination 
rate among adolescent females in Georgia. 
Ha3: There is an association between the provider visits and the HPV vaccine 
vaccination rate among adolescent females. 
RQ4: As Georgia did not expand Medicaid under ACA, is there any association 
between race and the HPV vaccination rate among adolescent females in Georgia? 
H04: There is no association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
Ha4: There is an association between race and the HPV vaccination rate among 
adolescent females in Georgia. 
 In this chapter, I focus on analyzing secondary data of the U.S. NIS-Teen data 
from 2011–2015 obtained from the CDC pertaining to adolescent females living in 
87 
 
Georgia. The sample size for analysis was 1,500. In Chapter 4, I explain the procedures 
of data collection, statistical results, and summary, including the transition to Chapter 5.   
Data Collection 
Procedures for Data Collection 
The data used for this study were secondary data, obtained from the NIS-Teen 
from 2011 to 2015. The NIS-Teen survey was conducted nationally and annually among 
adolescents ages 13-17 years living in noninstitutionalized households in the United 
States (CDC, 2015). Data collected from the 2011–2015 NIS-Teen survey had an average 
response rate of 58.7%. Also, it was noted that 31.8% of responses missed answering 
questions regarding health insurance. The data were open to the public and were accessed 
from the CDC home page. The NIS public-use data file was available in ASCII format. 
The data were downloaded using the SAS program to convert the data from an ASCII file 
to a readable format. The data were grouped by state, gender, race, HPV vaccination rate, 
insurance, provider visits, and demographics. The measures and instrumentation applied 
during data collection by the CDC minimized the risk to the reliability and validity of the 
secondary data used for this study. 
 For this study, only females ages 13 to 17 living in Georgia who reported ever 
receiving any HPV shots from 2011 to 2015 were sampled. The sample size for the study 
was 1,500, representing an estimated 303,920 girls ages 13 to 17 living in Georgia from 
2011 to 2015, extracted from the database. With an alpha=.05 and power=0.80, the 
projected sample size needed with this effect size was approximately 710, with at least 
142 respondents for every year of survey data. The sample size was 1,500, which 
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included 330 from the year 2011, 240 from the year 2012, 220 from the year 2013, 332 
from the year 2014, and 378 from the year 2015. The sample size was more than 
adequate for the objective of this study. It also allowed for expected attrition and the 
additional objectives of controlling for possible mediating moderating factors and 
subgroup analysis. There were no discrepancies in data collection from the plan presented 
in Chapter 3. 
Definition of Key Study Variables 
HPV testing history was defined using the question "Has teen ever received any 
human papillomavirus shots?" Respondents who answered yes were defined as having 
received the HPV vaccination. Respondents who answered no were defined as having 
never been vaccinated for HPV. Additional demographic information included age (13-
17) and race/ethnicity (non-Hispanic White, non-Hispanic Black, other non-Hispanic race 
or multiple races, and Hispanic). Health-related covariates included current health 
insurance coverage (yes and no) and whether the teen visited the doctor (provider visits) 
in the past 12 months (yes and no). 
Statistical Analysis 
The SAS-Callable SUDAAN software (Release 10.0, Research Triangle Institute, 
and NC) was used to generate prevalence estimates of health insurance coverage, HPV 
vaccination history, and doctor visits of teenage girls aged 13-17 living in the state of 
Georgia from 2011 to 2015. All analyses accounted for the complex NIS-Teen survey 
design and data weights. Logistic regression analyses were used to calculate prevalence, 
PRs, and 95% CIs for each independent variable to assess the association with every 
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outcome measures of this study. For the multivariable analyses, all significant study 
variables were controlled (p<0.05) to calculate the adjusted APRs. 
PRs derived from multivariate logistic regression models were used to test the 
null hypotheses for the four research questions. Covariates included in the multivariate 
models were selected based on statistically significant associations with the outcome 
variable at p <0.05, as described in the methods section. The 95% CI was used in 
determining statistically significant differences within response categories of independent 
covariates. Within the context of each variable, I included the multivariate model being 
significant at p < 0.05. It was more appropriate to use the 95% CI to determine 
statistically significant differences between response categories to test the null 
hypothesis.  
Also, chi-square was used to test bivariate associations between key study 
variables that included insurance coverage, provider visit, race/ethnicity, and HPV 
vaccination. These variables were categorical and were not adjusted for other covariates 
in a multivariate model. The chi-square test was appropriate to use for these analyses 
given the structure of the data and the parameters needed to substantiate the statements 
made in the results section below. 
Results 
Participants Characteristics 
 I examined the NIS-Teen data sets from 2011 to 2015 of adolescent females who 
were residents of Georgia within this period. The total population sampled was 1,500 
from ages 13 to 17 years. Table 1 presents selected the sociodemographic characteristics 
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of adolescent females who were residents of Georgia from 2011 to 2015. The overall 
sample size and weighted percentages were included. For the years the study was 
conducted, the sampled population for the years were 330 from 2011, 240 from 2012, 
332 from 2014, and 378 from 2015. Cumulatively, the 5 years of data collected among 
the sampled population of adolescent females ages denoted that many of the participants 
were 14-years-old (331, 22.0%) and 16-years-old (319, 21.3%). The CI was applied to 
determine if the sample size used was reflective of the population. The 95% CIs refer to 
the degree of error attributed to the proportion of the weighted sample populations for 
each year of the NIS-Teen. 
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Table 1 
Sociodemographic Characteristics of Adolescent Females Residing in Georgia Ages 13 - 
17 
Sociodemographic variables Adolescent female Georgia 
residents (N=1,500)  
 
  N % 95% CI  
Age        
13 285 18.9 16.4 - 21.6  
14 331 22.0 19.4 - 24.8  
15 280 18.9 16.4 - 21.7  
16 319 21.3 18.8 - 24.1  
17 285 18.9 16.5 - 21.6  
Race/Ethnicity        
Hispanic 150 12.6 10.4 - 15.1  
Non-Hispanic white 839 45.5 42.3 - 48.7  
Non-Hispanic black 406 35.1 31.9 - 38.5  
Non-Hispanic other/multiple races 105 6.8 5.4 - 8.7  
Survey year        
2015 378 20.4 18.5 - 22.4  
2014 332 20.2 18.2 - 22.4  
2013 220 19.9 17.7 - 22.3  
2012 240 19.7 17.3 - 22.3  
2011 330 19.8 17.8 - 22.0  
Note. Data derived from the NIS-Teen 2011 – 2015 
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According to Table 1, a greater proportion of adolescent females were non-
Hispanic White (839, 45.5%), followed by non-Hispanic Black (40, 35.1%), Hispanic 
(150, 12.6%) and non-Hispanic other/multiple races (105, 6.8%; 95% CI, 5.4–8.7). 
Accounting for a 95% degree of possible error, the proportion of non-Hispanic White 
females could be between 42.3% and 48.7%. 
Research Question 1 
For this research question, the independent variable was ACA (insurance), and the 
dependent variable was the HPV vaccination rate. The association of ever being 
vaccinated for HPV was examined while adjusting for health insurance coverage under 
ACA and other significant covariates (Table 2). As shown in Table 2 from 2011 to 2015, 
47.7% (APR= 1.27, 95% CI: 0.76 -1.49) of adolescent females were insured, while 
37.9% were uninsured among the sampled population. The rate of HPV vaccination 
trended up from 36.5% in 2011 to 46.7% in 2015. Most gains in HPV vaccination 
occurred in 2013 (53.5%) and 2014 (58.6%). Further, Table 2 below shows the rate of 
HPV vaccination after the implementation of the ACA, which was significantly 
associated with increasing age: age 14 (APR=1.36, 95% CI=1.01 – 1.85), age 16 
(APR=1.49, 95% CI=1.10 – 2.01), and age 17 (APR=1.65, 95% CI=1.23 – 2.20). 
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Table 2 
HPV Vaccination Rate Adjusted for Insurance Coverage After ACA Enactment 
 
Ever Been Vaccinated for HPV 
Sociodemographic 
variables 
Prevalence % PR 
PR (95% 
CI) 
APR APR (95% CI) 
Age           
13 37.2 Reference Reference 
14 43.5 
1.17 
0.89 - 
1.53 
1.36 1.01 - 1.85 
15 44.0 
1.18 
0.89 - 
1.57 
1.33 0.97 - 1.82 
16 53.1 
1.43 
1.11 - 
1.84 
1.49 1.10 - 2.01 
17 56.4 
1.52 
1.18 - 
1.95 
1.65 1.23 - 2.20 
Race/Ethnicity           
Hispanic 43.5 
0.90 
0.70 - 
1.16 
    
Non-Hispanic white 48.2 Reference   
Non-Hispanic black 47.0 
0.97 
0.82 - 
1.16 
    
Non-Hispanic 
other/multiple races 44.3 
0.92 
0.67 - 
1.26 
    
Survey year           
2015 46.7 
1.28 
1.01 - 
1.62 
1.42 1.08 - 1.87 
2014 58.6 
1.60 
1.28 - 
2.02 
1.72 1.33 - 2.23 
2013 53.5 
1.46 
1.14 - 
1.89 
1.42 1.05 - 1.91 
2012 40.3 
1.10 
0.82 - 
1.48 
1.06 0.76 - 1.49 
2011 36.5 Reference Reference 
Health insurance status           
Insured 47.7 
1.26 
0.87 - 
1.81 
1.27 0.88 - 1.82 
Uninsured 37.9 Reference Reference 
Note. Data obtained from the NIS-Teen 2011–2015Note: Reference is the category used 
in comparing other categories in the table. 
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In Table 2, the PR was calculated using the logistic regression model. Predicted 
marginal (prevalence) estimates were averaged over the possible response categories and 
compared to a reference category in the bivariate analysis. Covariates that were 
significantly associated in the bivariate were included in the multivariate analysis. The 
resulting PRs were a better alternative than using odds ratios because of their increased 
precision and ease of interpretation. The covariates included, as found in the 
sociodemographic variables, were age and race/ethnicity, while insurance was the 
independent variable and HPV vaccine was the dependent variable. Table 3 reports the 
health insurance coverage of the sampled population. Table 4 shows the results for RQ1. 
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Table 3 
Prevalence and Adjusted Prevalence Ratios of Adolescent Females with Health 
Insurance; NIS-Teen 2011-2015 
 
Have Health Insurance 
Sociodemographic 
variables 
Prevalence % PR 
PR (95% 
CI) 
APR APR (95% CI) 
Age           
13 91.3 Reference     
14 92.5 1.01 0.95 - 1.08     
15 90.5 0.99 0.91 - 1.08     
16 89.1 0.98 0.90 - 1.05     
17 85.2 0.93 0.84 - 1.03     
Race/Ethnicity           
Hispanic 72.1 0.76 0.66 - 0.89 0.76 0.66 - 0.89 
Non-Hispanic 
white 94.3 
Reference Reference 
Non-Hispanic 
black 91.4 
0.97 0.92 - 1.02 0.97 0.92 - 1.02 
Non-Hispanic 
other/multiple 
races 85.9 
0.91 0.79 - 1.04 0.91 0.80 - 1.04 
Survey year           
2015 90.7 1.03 0.94 - 1.12 1.04 0.95 - 1.13 
2014 87.3 0.99 0.90 - 1.09 1.06 0.98 - 1.15 
2013 93.1 1.06 0.98 - 1.14 1.06 0.98 - 1.15 
2012 90.6 1.03 0.94 - 1.12 1.04 0.95 - 1.13 
2011 88.1 Reference Reference 
Health insurance 
status   
        
Insured 47.7 1.26 0.87 - 1.81 1.27 0.88 - 1.82 
Uninsured 37.9 Reference Reference 
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Table 4 
Hypothesis Test for Research Question 1 Insurance and HPV Vaccine for the Sampled 
Years 2011-2015 
Hypothesis Test                   
Test Statistic DF Value P-Value 
CHISQ (Obs - Exp)    
Wald-F 1 1.8487 0.1739 
 
Chi-square was used to test the bivariate association between insurance and HPV 
vaccine in RQ 1. The test result denoted a p-value of 0.1739 (p >0.05) significance level 
as found in Table 4. The result of the chi-square supported the null hypothesis. H01: 
There is no association between ACA (insurance) and the HPV vaccination rate among 
adolescent females in Georgia. The p-value of 0.1739 indicated that there was a 
probability of 0.1739 that the sample statistic that I recorded could have occurred given 
my null hypothesis. Due to the probability being high in comparison to the significance 
level, there was not sufficient evidence to denote that a significant difference existed.  
Based on the years surveyed, the insurance coverage after the implementation 
from 2011 was 88.1%, 2012 was 90.6% (APR =1.04, 95%; CI [0.95 – 1.13]), 2013 was 
93.1% (APR= 1.06, 95% CI [0.98 -1.15]), but fell in 2014 to 87.3% (APR= 1.06, CL 
[0.98 -1.15]), and rose in 2015 to 90.7% (APR= 1.04, CI [0.95 – 1.13]). Most of the 
adolescent females had health insurance (89.9%, 95% CI, 87.2 – 93.1). Figure 1 
illustrates the rate of HPV vaccination by health insurance status. 
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Figure 1. Prevalence of HPV vaccination by insurance status from 2011-2015. 
Compared to the baseline year of 2011, the rate of HPV vaccination increased 
among insured adolescent females residing in Georgia from 35.3% to 53.9% in 2015. The 
highest increase occurred between 2014 and 2015 when HPV vaccination by insurance 
status was higher than the uninsured. 
The result based on p-value suggested that ACA (health insurance) was not 
significantly associated with the HPV vaccination rate. However, the percentage of 
adolescent females who were vaccinated for HPV increased from 36.5% in 2013 to 
58.6% in 2014, and for each year after 2012, adolescent females were more likely to be 
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vaccinated for HPV: 2013 (APR=1.42, 95% CI [1.05–1.91]), 2014 (APR=1.72, 95% CI 
[1.33 2.23]), 2015 (APR=1.42, 95% CI [1.08 – 1.87]). However, in 2013, the most 
significant increase in vaccination was among the uninsured but fell below the insured in 
both 2014 and 2015 steadily. HPV vaccination during the implementation of the ACA 
was also significantly associated with increasing age: age 14 (APR=1.36, 95% CI [1.01–
1.85]), age 16 (APR=1.49, 95% CI [1.10–2.01]), age 17 (APR=1.65, 95% CI [1.23–
2.20]). 
Research Question 2 
The percentage of adolescent females who visited a health care provider varied by 
insurance status from 2011 to 2015 (Figure 2). Adolescent females with health insurance 
consistently had a higher rate of health care provider visits than those without health 
insurance after the enactment of the ACA as found in Table 4. From 2011 to 2015, 87.2% 
(APR =1.49, 95% CI [1.21-1.85]) of insured adolescents and 54.5% of the uninsured 
adolescent females visited the health providers. Table 5 illustrates the rate of provider 
visits by the adolescent females residing in Georgia after the implementation of the ACA 
in 2011. Table 6 shows the association between insurance and provider visit. 
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Table 5 
Prevalence and Adjusted Prevalence Ratios of Provider Visits; NIS-Teen 2011- 2015 
 
Health Care Provider Visits 
Sociodemographic 
variables 
Prevalence % PR PR (95% CI) APR APR (95% CI) 
Age           
13 87.3 Reference     
14 82.2 0.94 0.87 - 1.02     
15 83.4 0.96 0.87 - 1.05     
16 84.1 0.96 0.89 - 1.04     
17 81.4 0.93 0.85 - 1.02     
Race/Ethnicity           
Hispanic 65.8 0.75 0.64 - 0.87 0.87 0.76 - 0.99 
Non-Hispanic white 88.0 Reference Reference 
Non-Hispanic black 83.7 0.95 0.89 - 1.01 0.97 0.89 - 1.05 
Non-Hispanic 
other/multiple races 87.5 
0.99 0.91 - 1.08 1.06 0.98 - 1.15 
Survey year           
2015 81.0 1.00 0.93 - 1.14 1.02 0.93 - 1.13 
2014 85.3 1.05 0.96 - 1.15 1.04 0.94 - 1.14 
2013 87.0 1.07 0.97 - 1.17 0.99 0.88 - 1.12 
2012 83.5 1.03 0.93 - 1.14 1.03 0.93 - 1.15 
2011 81.4 Reference Reference 
Health insurance status           
Insured 87.2 1.60 1.26 - 2.03 1.49 1.21 - 1.85 
Uninsured 54.5 Reference Reference 
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Table 6 
Hypothesis Test for Research Question 2 Insurance and Provider Visit for the Sampled 
Years 2011-2015 
Hypothesis Test                   
Test Statistic DF Value P-Value 
CHISQ (Obs - Exp)    
Wald-F 1 16.9608 0.0000 
 
During subsequent years, the rate of provider visits was the following: 2012 was 
83.5% (APR =1.03, 95% CI [0.93-1.15]); 2013 was 87.0% (APR = 0.99, 95% CI [0.88 -
1.12]); 2014 was 85.3 % (APR = 1.04, 95% CI [0.94 -1.14]); and 2015 was 81.0% 
(APR= 1.02, 95% CI [0.93 – 1.13]). Most of the adolescent females visited the doctor in 
the past 12 months before the interview (83.6%, 95% CI, 81.0– 86.0) and had health 
insurance (89.9%, 95% CI, 87.2 – 93.1). 
 The result denoted a p-value of 0.0000 (p< 0.05) significance level, which was 
statistically significant. The p < 0.05 indicated a strong association between ACA and 
provider visit, thereby supporting the alternative hypothesis. Ha2: There is an association 
between the ACA and the rate of provider visit among adolescent females in Georgia. 
Figure 2 shows the significant association between the ACA and the rate of provider 
visit. 
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Figure 2. Prevalence of provider visits by insurance status from 2011-2015. 
Research Question 3 
After adjusting for significant study variables, adolescent females with health 
insurance were 1.49 times more likely (APR=1.49, 95% CI [1.21–1.85]) to visit their 
health care provider than those without health insurance. The HPV vaccination was 
significantly associated with health care provider visits as well (Table 7 and Figure 3). In 
addition, 50% of adolescent females who visited their health care provider in the past 12 
months were vaccinated for HPV and were 56% more likely to receive the HPV 
vaccination than those who did not visit their health care provider (APR=1.56, 95% CI 
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[1.20 – 2.03]). Also, 50% (APR=1.56, 95% CI [1.20 -2.03]) of the sampled population 
indicated that they visited their provider in the past 12 months.  
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Table 7 
Prevalence and Adjusted Prevalence Ratios for HPV Vaccination Adjusted for Provider 
Visits; NIS-Teen 2011-2015 
 
Ever Been Vaccinated for HPV 
Sociodemographic 
variables 
Prevalence % PR PR (95% CI) APR APR (95% CI) 
Age           
13 37.2 Reference Reference 
14 43.5 1.17 0.89 - 1.53 1.24 0.95 - 1.61 
15 44.0 1.18 0.89 - 1.57 1.21 0.92 - 1.60 
16 53.1 1.43 1.11 - 1.84 1.47 1.15 - 1.89 
17 56.4 1.52 1.18 - 1.95 1.59 1.25 - 2.02 
Race/Ethnicity           
Hispanic 43.5 0.90 0.70 - 1.16     
Non-Hispanic white 48.2 Reference   
Non-Hispanic black 47.0 0.97 0.82 - 1.16     
Non-Hispanic 
other/multiple races 44.3 
0.92 0.67 - 1.26     
Survey year           
2015 46.7 1.28 1.01 - 1.62 1.29 1.03 - 1.61 
2014 58.6 1.60 1.28 - 2.02 1.59 1.28 - 1.98 
2013 53.5 1.46 1.14 - 1.89 1.44 1.14 - 1.83 
2012 40.3 1.10 0.82 - 1.48 1.11 0.83 - 1.47 
2011 36.5 Reference Reference 
Visited the doctor 
within the past 12 
months   
        
Yes 50.0 1.57 1.20 - 2.03 1.56 1.20 - 2.03 
No 32.0 Reference Reference 
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Table 8 
Research Question 3: Provider Visit and HPV Vaccination for Years 2011-2015 
Hypothesis Test                   
Test Statistic DF Value P-Value 
CHISQ (Obs - Exp)    
Wald-F 1 14.3670 0.0002 
 
I used a chi-square to test the association between provider visit and the HPV 
vaccination. I found denoted a p-value (p 0.0002), which was statistically significantly 
lower than (p <0.05). The result of the hypothesis test (p=0.0002) supported the 
alternative hypothesis. Ha3: There is a significant association between the provider visit 
and the HPV vaccination rate among adolescent females in Georgia. P <0.05 was 
statistically significant, denoting a strong association between provider visit and the HPV 
vaccination rate.  
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Figure 3. Prevalence of HPV vaccination and provider visits from 2011–2015. 
Research Question 4 
The health insurance coverage for non-Hispanic White was 94.3% (ref), non-
Hispanic Black was 91.4 % (APR= 0.97, CI [0.92 – 1.02]), and non-Hispanic 
other/multiple races was 85.9% (APR= 0.91, CL [0.80 -1.04]). After adjusting for 
significant study variables, Hispanic adolescent females were less likely to be insured 
compared to non-Hispanic adolescent females (APR=0.76, 95%, CI [0.66 – 0.89]). 
Hispanic females were less likely to visit their health care provider (APR=0.87, 95%, CI 
[0.87 – 0.99]) compared to non-Hispanic Whites. 
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The rate of adolescent females who received HPV vaccination increased for each 
racial/ethnic group from 2011 to 2015 (Figure 4). The most substantial increase occurred 
among Hispanic and non-Hispanic Black females, in which the HPV vaccination rate 
rose from 26.1% and 41.7% in 2012 to 65.5% and 58.4% in 2013 for Hispanics and non-
Hispanic Black females, respectively. There was a general increase in HPV vaccination 
from 39.2% in 2011 to 50.5% in 2015 among adolescent females regardless of race. 
Table 9 shows the results for RQ 4. Figure 4 shows the prevalence of HPV vaccination 
by race/ethnicity from 2011-2015. 
Table 9 
Research Question 4: Race/Ethnicity and HPV Vaccination the Years 2011-2015 
Hypothesis Test                   
Test Statistic DF Value P-Value 
CHISQ (Obs - Exp)    
Wald-F 3 0.2845 0.8366 
 
I found that the p-value was (p 0.8366) was greater than (p >0.05) statistical 
significance level. This result indicated that race/ethnicity was not strongly associated 
with the HPV vaccination rate. The output result supported the null hypothesis. H04: 
There is no association between race/ethnicity and the HPV vaccination rate among 
adolescent females in Georgia. 
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Figure 4. Prevalence of HPV vaccination by race/ethnicity from 2011-2015. 
 
Summary 
 Chapter 4 contained the introduction that comprised of the purpose, research 
questions, hypotheses and preview of the organization, and data collection. Descriptive 
statistics that characterized the sampled population were presented based on variance 
estimation computed using the Taylor linearization method. Linear regression was run on 
NIS-Teen data individually and collectively to compare the dependent variable to the 
independent variables. Logistic regression was used to calculate the prevalence, PRs, and 
95% CIs for each independent variable to assess the association with the outcome 
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measures of this study. For the multivariable analyses, all significant study variables were 
controlled (p<0.05) to calculate the APRs. 
The data analysis for this study was generated using SAS-Callable SUDAAN 
software (Release 10.0, Research Triangle Institute NC, 2012) of the NIS-Teen data from 
2011–2015. The analysis of the results was presented and discussed in sequence, which 
consisted of the demographics, each research question, hypotheses, and the data analysis 
pertinent to each question. Discussion involved the analysis of each independent variable 
in determining whether or not the results supported either the null or alternative 
hypothesis. 
Four research questions and independent variables, including hypotheses, were 
examined through chi-square tests. Two of the research questions and hypotheses 
supported the alternative hypotheses: RQ2: Is there any association between ACA with 
no cost-sharing and the rate of provider visit among adolescent females in Georgia? RQ3: 
Is there any association between provider visits and the HPV vaccination rate among 
adolescent females in Georgia? On the contrary, RQ1 supported the null hypothesis: Is 
there any association between ACA with no cost-sharing and the HPV vaccination rate 
among adolescent females in Georgia? However, it was noted that 31.8% of responses 
missed answering questions regarding health insurance. Finally, RQ4 supported the null 
hypothesis indicating that there was no association between race/ethnicity with the HPV 
vaccination rate. I found that the prevalence of adolescent females who received the HPV 
vaccination increased for each racial/ethnic group from 2011 to 2015. The interpretation 
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of findings, limitations of the study, recommendations, implication for social change, and 
conclusion are found in Chapter 5. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The use of the HPV vaccine remained below the Healthy People 2020 target for 
adolescent females in Georgia, although the HPV virus is the most prevalent cause of 
STDs among teenage females in the United States (CDC, 2015; Satterwhite et al., 2013) 
and cancers in adulthood (Dunne et al., 2014). HPV is associated with cervical and 
oropharyngeal cancers, which are prevalent in Georgia and are above the national 
average (Berzen et al., 2016). Also, the mortality rate for cervical cancer, oral cavity, and 
pharynx cancers are 2.6% (National Cancer Institute, n.d.). The potential barrier noted for 
the decreased use of the HPV vaccine was cost resulting from out-of-pocket expenses for 
those with private insurance and the uninsured. This quantitative secondary data analysis 
of NIS-Teen data was conducted to explore if there was an association between the ACA 
and the use rate of the HPV vaccine among adolescent females in Georgia after its 
enactment.   
I found that there was a strong association between the ACA and provider visits 
(83.6%, 95% Cl, 81.0–86.0), and 89.9% of adolescent females had health insurance. The 
provider visit was statistically significantly associated with increased rate of HPV 
vaccination p=0.0002 (p<0.05). 
Compared to the baseline year of 2011, the rate of HPV vaccination increased 
among the insured adolescent females in Georgia from 35.3% to 53.9% in 2015. From 
2011–2012, HPV vaccinations among the uninsured decreased from 43.7% to 25.3%, 
rose sharply to 73.5% in 2013, and then declined to 18.0% in 2015. 
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There was no significant association between the ACA and the HPV vaccination 
rate based on the analysis. However, the analysis of the other covariates in this study 
denoted a steady increase in HPV vaccination rate, such as provider visit and 
race/ethnicity, including age. I found an increase in the HPV vaccination rate from 39.2% 
in 2011 to 50.5% in 2015 among adolescent females, regardless of race/ethnicity. The 
most gain occurred among Hispanic and non-Hispanic Black females, in which the rate of 
HPV vaccination rose from 26.1% and 41.7% in 2012 to 65.5% and 58.4% in 2013 
respectively. 
The results of the increased use of HPV vaccine suggested that 31.8% of the 
missed responses to the questions about health insurance likely distorted the outcome 
result of the association between the ACA and the HPV vaccine. The missing data for the 
health insurance questions were due to the failure of respondents to complete the sections 
of the interview pertaining to insurance. 
Interpretation of the Findings 
The findings of this quantitative secondary data analysis relating to the 
independent variables and the dependent variable of HPV vaccination rate, including 
whether the results supported the alternative or null hypothesis of each research question, 
were reported in Chapter 4. The interpretation of the findings of this secondary data 
analysis can be compared with the findings of the literature review in Chapter 2 by 
discussing the four research questions. 
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Research Question 1 
Is there any association between the ACA with no cost-sharing and the HPV 
vaccination rate among adolescent females in Georgia? 
I found that there was no statistically significant association between the ACA 
and the rate of HPV vaccination (p = 0.1739, p > 0.005). However, the logistic regression 
analyses showed that adolescent females in Georgia were 1.42 times more likely to be 
vaccinated in 2013 (95% CI, 1.05–1.91), 1.72 times in 2014 (95% CI, 1.33–2.23), and 
1.42 times in 2015 (95% CI, 1.08–1.87). Also, adolescent females were 1.36 times more 
likely to be vaccinated at age 14 (95% CI, 1.01–1.85), 1.49 times at age 16 (95% CI, 1.10 
–2.01), and 1.65 times age 17 (95% CI, 1.23–2.20). 
Although I found that there was no significant association between the ACA and 
the HPV vaccination rate, I found that the rate of HPV vaccination steadily increased for 
the insured teens and fluctuated among the uninsured. Further, among the uninsured teen 
females, the highest increase in HPV vaccination occurred in 2013. Also, the 95% CI 
showed the positive effect of the ACA on the HPV vaccination rate. The result was likely 
skewed because 31.8% of responses missed the questions about health insurance, which 
probably impacted the result. 
These findings conflicted with the literature in Chapter 2. Shen et al. (2014) 
estimated how immunization rate might improve if cost-sharing was removed. Shen et al. 
focused on changes in vaccination rates and spending associated with extending first-
dollar coverage to privately insured children for four childhood vaccines. Shen et al. 
revealed that 36.9% of adolescents with private insurance received at least one dose of 
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the HPV vaccine. Eliminating cost-sharing had an estimated effect of 40,000 additional 
HPV immunizations (Shen et al., 2014). Shen et al. suggested that vaccination rates 
would increase modestly, and the increases would be more substantial for those currently 
facing cost-sharing. The data analysis on RQ1 in Chapter 4 revealed that, compared to the 
baseline year of 2011, the rate of HPV vaccination increased among insured adolescent 
females in Georgia from 35.3% to 53.9% in 2015. 
Also, the KFF’s (2016) review on HPV vaccine access and use in the United 
States reported that the uptake and awareness of the HPV vaccine have slowly improved. 
The KFF noted that the HPV vaccination rates significantly increased in five states, and 
Georgia was one of the states, between 2013 and 2014. The result was confirmed by the 
analysis in Chapter 4 on RQ1 that showed that the rate of adolescent females who were 
vaccinated for HPV increased from 36.5% in 2013 to 58.6% in 2014. Also, for each year 
after 2012, adolescent females were more likely to be vaccinated.  
Both findings in the literature disconfirmed the null hypothesis but confirmed an 
increase in HPV vaccination rate, mostly among the insured in this study. I found out that 
the missing values relating to insurance coverage of the respondents likely distorted the 
outcome. However, the remaining data for health insurance coverage were sufficient to 
produce estimates representative of the state of Georgia, as noted in the analysis of RQ1. 
Further, the outcome of the analysis of RQ1 extended knowledge. I found that the 
HPV vaccination was significantly associated with increasing age. I found that adolescent 
females were 1.36 times more likely to be vaccinated at age 14, 1.49 times at age 16, and 
1.65 times at age 17 years. Reijneveld et al. (2014) assessed the use of care among 2,230 
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adolescents by type and age. Reijneveld et al. identified that the overall use of services 
increased with age (predisposing factor).  
Research Question 2 
Is there any association between the ACA with no cost-sharing and the rate of 
provider visit among adolescent females in Georgia? 
I found that the insurance coverage after the implementation of the ACA rose 
from 88.1% in 2011 to 90.6% (APR = 1.04, 95% CI [0.95–1.13]) in 2012, 93.1% (APR= 
1.06, 95% CI [0.98 1.15]) in 2013, but fell in 2014 to 87.3% (APR= 1.06, CI [0.98-1.15]) 
and increased in 2015 to 90.7% (APR = 1.04, CI [0.95 – 1.13]). The proportion of 
adolescent females with health insurance was between 87.2%-93.1% based on 95% CI. 
From 2011 to 2015, adolescent females with health insurance were 1.49 times more 
likely (95% CI, 1.21–1.85, P < 0.0001) to visit their health care provider than the 
uninsured. I found a statistically significant degree of association between the ACA and 
provider visits. I found that 50% (APR= 1.56, 95% CI [1.20 2.03]) of the sampled 
population visited their provider in the past 12 months.  
This finding is similar to Tebb et al. (2015) who examined the level of  the health 
care of teens during the implementation phases of the ACA. Tebb et al. revealed that the 
proportion of adolescents and children who were uninsured dropped from 10% to 5.5% in 
2012 after the implementation of the ACA. The increase in insurance rates among the 
teens was credited with increased access to provider visits (Tebb et al., 2015).  
Also, Weller et al. (2003) conducted a cross-sectional study on CSHCN to 
determine how sociodemographic factors and type of insurance influence use of medical 
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and health-related services. Weller et al. identified that enabling factor (insurance) was 
associated with the use of health services. This finding is similar to the result of RQ2 that 
showed that adolescent females with health insurance (enabling factor) were 1.49 times 
more likely to visit their health care provider. 
Hall and Lord (2014) noted that the significant achievement of the ACA was the 
expansion of Medicaid to low-income families near the poverty line and the provision of 
subsidies for those above the poverty threshold to buy insurance from the established 
marketplace or insurance exchanges. Also, Curtis et al. (2014) reported that the ACA 
aimed at expanding access to preventive services by establishing a mandatory fund for 
CHCs and SBHCs to provide health care services to the uninsured and underserved 
populations. These provisions of the ACA increased access to the providers, as depicted 
in the result of this analysis for RQ2.  
Research Question 3 
Is there any association between provider visits and the HPV vaccination rate 
among adolescent females in Georgia? 
I found that adolescent females with health insurance were 1.49 times more likely 
(95% CI, 1.21–1.85) to visit their health care provider than those without health 
insurance. In addition, 50% (APR=1.56, 95% CI [1.20 -2.03]) of the sampled population 
visited their provider within 12 months. Also, 50% of adolescent females who visited 
their health care provider in the past 12 months were vaccinated for HPV and were 56% 
more likely to receive an HPV vaccination (APR =.56, 95% CI [1.20 – 2.03], p <0.0002). 
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I found a statistically significant strong association between provider visits and the rate of 
HPV vaccination. A high degree of association was noted based on the 95% CI. 
This finding was confirmed by Farmar et al. (2016) who examined the effects of 
implementing bundling of vaccines, offering vaccines on every visit and using standard 
orders in an integrated urban safety net health system among teen females. Farmar et al. 
found an increased rate of HPV coverage of ≥1 dose of 89.8% for females between 13 to 
17 years, compared to national rates of 57.3% (Farmar et al., 2016). Also, the rates of 
HPV coverage (≥3 doses) were 66.0% for the sampled population compared to the 
national rate of 37.6% at the same period (Farmar et al., 2016). Farmar et al. revealed that 
bundling of vaccines during each provider visit minimized missed opportunities, which 
led to a higher vaccination rate in this health clinic.   
Stokley et al. (2013) examined the rate of HPV vaccination among adolescent 
females using the data from 2007–2012 NIS-Teen survey depicted increased missed 
opportunities for HPV vaccination. Stokley et al. identified that 84% of unvaccinated 
girls had provider visits where another vaccine was given. Stokley et al. noted that if the 
HPV 3 dose series was started at these visits, the use of ≥1 dose could have risen to 
92.6%. 
Also, Vadaparampil and Perkins (2014) indicated that the adoption of provider 
practices to use acute or problem visits to initiate and provide catch-up vaccinations has 
the potential to increase the uptake of the HPV vaccine. Further, Gable et al. (2016) 
reported that the timeline recommended for the HPV vaccination corresponds to the 
vaccination series for Tdap and MCV4. Starting the HPV vaccine series during every 
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health care encounter can enhance the opportunities for improving vaccine coverage. 
Taking advantage of every health care encounter or provider visit provides opportunities 
for provider recommendation of the HPV vaccine. I found in the analysis of RQ3 that 
50% of adolescent females who visited their health care provider in the past 12 months 
were vaccinated for HPV and were 56% more likely to receive the HPV vaccination. 
The Georgia Health Policy Center (2012) reported that the funding for the ACA 
provided community-based prevention, clinical prevention, infrastructure, and workforce, 
including research and data collection. Part of the funding was used in establishing 
SBHCs in three counties in Georgia based on the need assessment: Ware, Berrien, and 
DeKalb counties (Georgia Health Policy Center, 2012). All of these infrastructures aim at 
improving access and quality of preventive services for adolescents (Curtis et al., 2014). 
The infrastructures created a regular source of care that was linked with increased use of 
health services (Babitsch et al., 2012). Expanding access with no cost-sharing with the 
infrastructures subsequently increased provider visits and usage of the HPV vaccine, as 
denoted in the analysis of RQ3. Dixon and Hertelendy (2014) noted that the 
implementation of the ACA increased access to insurance and preventive services 
coverage. 
Research Question 4 
As Georgia did not expand Medicaid under ACA, is there any association 
between race and the HPV vaccination rate among adolescent females in Georgia? 
I found in the results of RQ4 that there was no association between race and HPV 
vaccination rate, although Georgia did not expand Medicaid. The rate of adolescent 
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females who received the HPV vaccination increased for each racial/ethnic group from 
2011 to 2015, with (p = 0.8366) (p >0.05). The most substantial increase occurred among 
Hispanic and non-Hispanic Black females where HPV vaccination rose from 26.1% and 
41.7% in 2012 to 65.5% and 58.4% in 2013. The general increase in HPV vaccination 
from 39.2% in 2011 to 50.5% in 2015 occurred among adolescent females regardless of 
race. Although Georgia did not expand Medicaid, race/ethnicity did not have a statistical 
significance on the HPV vaccination rate, as there was a general increase in all 
races/ethnicities. 
 Bednarczyk et al. (2017) evaluated the patterns of the HPV vaccine uptake by 
race/ethnicity and poverty status using the NIS-Teen data from 2008 -2011. Bednarczyk 
et al. indicated Hispanic females had the highest increase in initiation and uptake of HPV 
vaccine by 2011, 44.4% and 20.6 % respectively. However, the findings in this current 
study showed that the most increase occurred among Hispanic and non-Hispanic Black 
females where HPV vaccination rose from 26.1% and 41.7% in 2012 to 65.5% and 
58.4% in 2013 respectively. Also, there was an increase in HPV vaccination from 39.2% 
in 2011 to 50.5% in 2015 among adolescent females regardless of race in Georgia.  
Niccolai et al. (2011) assessed the effects of race/ethnicity, poverty, and 
completion of the three-dose HPV vaccine series among those who initiated vaccination. 
The study was conducted among adolescent females, ages13 to 17 years, using data from 
the 2008-2009 NIS-Teen. The sampled population was (n=7606), and analysis was done 
with logistic regression to adjust for covariates and measures of access to care from 2010-
2011 (Niccolai et al., 2011). Niccolai et al. revealed that 55% of adolescent girls 
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completed the three series, but on controlling covariates, variation existed based on race. 
Black (AOR = 0.48, 95% CI [0.40, 0.57]) or Hispanic (AOR= 0.75, 95% CI [0.64, 0.88]) 
were significantly less likely to complete vaccination than Whites (Niccolai et al., 2011). 
ACA expanded access and provided infrastructures to improve access irrespective of race 
or ethnicity. However, some states’, including the state of Georgia, refusal to expand 
Medicaid has the potential of hindering access to preventive services such as HPV 
vaccine, resulting from disparity associated with race. However, the infrastructures and 
funding the ACA provided, and the VFC program, could enhance the use of the HPV 
vaccine. The foundations could explain the current finding on RQ4 that showed an 
increase in HPV vaccination among adolescent females regardless of race and non-
Medicaid expansion from 2011–2015 in Georgia.  
The result of the analysis of RQ4 was different from previous studies on 
race/ethnicity and HPV vaccination. Forsberg et al. (2014) assessed the HPV vaccination 
rate based on race/ethnicity on adolescent females and observed differences in access. 
Forsberg et al. identified that Hispanics were more likely than Whites or Blacks to initiate 
the HPV vaccine. However, White teens were most likely to complete the three-vaccine 
series (Forsberg et al., 2014). Also, Jeudin et al. (2014) reported that low-income and 
minority adolescents were more likely to start the HPV vaccination series than White and 
higher-income adolescents but were less likely to complete the series. Although the series 
of HPV vaccination was not included in the analysis of the current study, I found that 
HPV vaccine uptake increased among all races from 39.2% in 2011 to 50.5% in 2015. 
The results of RQ4 supported the null hypothesis that race did not have an association 
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with HPV vaccination rate, although Georgia did not expand Medicaid, and the 
minorities (Hispanic and Blacks) are economically disadvantaged. 
Interpretation of the Findings in the Context of the Theoretical Framework 
Andersen’s BM of health care use was applied to this study. Andersen (1968) 
described health care use as the use of health care services by individuals for preventing, 
curing diseases, health promotion, and maintenance. Andersen initially postulated this 
behavioral model in 1968, where a three-stage model consisting of predisposing, 
enabling, and need components were used to expound on the divergent use of medical 
care services by families. Andersen developed this framework to determine situations of 
factors that aid or hinder individual's use of health services. This BM evolved as a 
multilevel model that incorporated both individual and contextual determinants of the use 
of health services (Babitsch et al., 2012). The BM consists of three factors: predisposing, 
enabling, and need factors (Andersen, 1968). 
As this behavioral model evolved, Anderson (1995) defined access in 
multidimensional terms using potential access as the existence of enabling resources that 
enhance the use. Realized access is the use of services. Equitable access is dependent on 
demographic characteristics and needs factors (Lo & Fulda, 2008), while inequitable 
access results when the social structure, health belief, and enabling resources demarcate 
medical usage (Andersen, 1995). In using the BM in fostering equitable access, a variable 
must point to changes in policy that could cause a change in behavior (Andersen, 1995). I 
focused on a policy change, which was the ACA, to ascertain if the change in policy 
could have influenced the use of HPV vaccine. 
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For this study, the variables analyzed were within the three factors that Andersen 
proposed that influence health care use. The variables examined were race/ethnicity 
(predisposing factor); insurance/ACA, usual source of care/rate of contact with the 
provider (provider visits) (enabling factor); and HPV vaccine (need factor). 
Race/Ethnicity for Predisposing Factors 
Race/ethnicity is a social factor that predisposes the use of health care services. 
The adolescents vary by race and ethnicity reflecting a diverse population with differed 
socioeconomic status (HHS, 2016). Racial minorities have less access to health care 
(HHS, 2016). Blacks are at higher risk of being uninsured than Whites (KFF, 2016). The 
disparity in insurance coverage was higher for Hispanics, who accounted for 20% of the 
nonelderly population but nearly a third (32%) of the nonelderly uninsured population 
(KFF, 2016). Hispanics and Blacks have significantly higher uninsured rates (17.2% and 
12.2%, respectively) than Whites (8.1%; KFF, 2016).  
Scholars who examined the HPV vaccination rate based on race/ethnicity 
observed differences in access (Forsberg et al., 2014). Also, Jeudin et al. (2014) evaluated 
the uptake of HPV vaccine among adolescent females and identified that Hispanics were 
more likely than Whites or Blacks to initiate the HPV vaccine. However, White teens 
were most likely to complete the three-vaccine series (Forsberg et al., 2014). Limited 
access and health disparities associated with race/ethnicity can result in low patient 
engagement with health providers and underuse of health services (Washington, 2014). 
Washington (2014) noted that lack of access or insurance coverage can impact the use of 
health care services among this group. 
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In this study, although Georgia did not expand Medicaid, race/ethnicity did not 
have statistical significance on the HPV vaccination rate. The highest increase occurred 
among Hispanic and non-Hispanic Black females. In both races, the HPV vaccination 
rate rose from 26.1% and 41.7% in 2012 to 65.5% and 58.4% in 2013 respectively. Also, 
there was an increase in the HPV vaccination from 39.2% in 2011 to 50.5% in 2015 
among adolescent females regardless of race in Georgia. The outcome could result from 
the expanded access provided by the ACA through the infrastructures established, no 
cost-sharing for preventive services, subsidies for families to purchase health insurance in 
the market place, and SCHIP. I found that race/ethnicity (predisposing factor) was not the 
most significant factor that enhanced use of the HPV vaccine. 
Insurance (ACA) and Provider Visits as Enabling Factors 
Enabling factors enhance the use of health services. The enabling factors 
applicable to this study were health insurance coverage (ACA) and provider visit (a 
regular source of care).  
Insurance (ACA) 
Being insured enhances the potential for significant use of health services while 
preventing delay in service in varied groups or population (Babitsch et al., 2012). The 
ACA aimed at making health care more accessible and affordable, while improving 
quality (Obama, 2016). The ACA was credited with reducing the uninsured rate from 
16.0% in 2010 to 9.1% in 2015, down by 43% (Obama, 2016). 
Before the ACA, a significant barrier to immunization was financial that involved 
out-of-pocket costs, and about 7% of individuals with private insurance encountered cost-
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sharing (Shen et al., 2014). Shen et al. (2014) reported that the rate of HPV vaccination 
was lower among adolescents who encountered cost-sharing. Shen et al. suggested that 
eliminating cost-sharing will increase compliance and vaccine uptake. In 2009, prior the 
enactment of the ACA, the vaccination rate for adolescents ages 13–17 years who 
received ≥1 HPV dose series in Georgia was 38.6% (Dorell et al. 2010).  
Underwood et al. (2015) investigated the receipt of the HPV vaccine series 1 and 
3 on both female and male adolescents, parental attitudes, and correlation of vaccine 
initiation and completion. Underwood et al. revealed that adolescents in high school with 
private insurance who encountered out-of-pocket expenses were at increased odds of 
completing three doses compared to those with Medicaid coverage. After the enactment 
of the ACA in 2010, the ≥1 HPV dose series coverage among teen females ages 13 to 17 
years increased from 53.1% and 65.4% between 2013 and 2014 (CDC, 2015). 
Based on the data analysis of RQ1, the ACA was not statistically significantly 
associated with HPV vaccine use. I found that, compared to the baseline year of 2011, the 
rate of HPV vaccinations increased among insured adolescent females in Georgia from 
35.3% to 53.9% in 2015. Also, from 2011–2012, the HPV vaccination rate among the 
uninsured decreased from 43.7% to 25.3%, rose sharply to 73.5% in 2013, and then 
declined to 18.0% in 2015. The outcome could be attributed to 31.8% of responses that 
missed questions regarding health insurance, which introduced bias to this result. 
However based on the 95% CI, adolescent females were significantly more likely to be 
vaccinated for HPV (ref = 2011): 2013 (APR=1.42, 95% CI [1.05–1.91]), 2014 
(APR=1.72, 95% CI [1.33–2.23]), 2015 (APR=1.42, 95% CI [1.08–1.87]).  
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Provider Visits (Enabling Factor) 
Provider visit is a health encounter that can occur in acute settings or well visits, 
and these are opportunities for vaccination (Stokley et al., 2013). A regular source of care 
was associated with increased use of health care services (Babitsch et al., 2012). Stokley 
et al. (2013) argued that every health care visit, for acute problems or back-to-school 
evaluations, is an opportunity to assess the immunization status of adolescents  
Stokley et al. (2013) reported there was increased missed opportunities for HPV 
vaccination while there was higher coverage of other vaccines recommended for 
adolescents within the same period after the evaluation of data from 2007–2012 NIS-
Teen survey. Stokley et al. noted that 84% of unvaccinated girls had provider visits where 
another vaccine was given. Stokley et al. identified that starting the HPV 3 dose series at 
these visits could have increased the use of ≥1 dose to 92.6%. Also, enhancing the use of 
the HPV vaccine in the United States was possible with the current infrastructure and 
health care use (Stokley et al., 2013).  
The ACA provided funding for CHCs, SBHC, and local health departments as a 
means of increasing and sustaining the infrastructure that offers safety net preventive and 
health care services (Curtis et al., 2014; Forsberg et al., 2014). The Georgia Health Policy 
Center (2012) reported that this funding was used to establish community-based 
prevention, clinical prevention, infrastructure, and workforce, including research and data 
collection in Georgia. The infrastructures the ACA aimed at improving access and quality 
of preventive services for adolescents (Curtis et al., 2014). These infrastructures created a 
regular source of care that was linked with increased use of health services (Babitsch et 
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al., 2012). Expanding access with no cost-sharing with the infrastructures subsequently 
increased provider visits and usage of HPV vaccine, as denoted in this analysis.    
Based on the findings of RQ2, the ACA was statistically significantly associated 
with provider visit (P < 0.0001), and provider visit in RQ3 was statistically significantly 
(p <0.0002) associated with increased HPV vaccination rate among adolescent in 
Georgia. In addition, 50% (APR=1.56, 95% CI [1.20-2.03]) of the sample population 
visited the provider in the past 12 months. Also, 56% of adolescent females were more 
likely to receive an HPV vaccination than those who did not visit their health care 
provider. 
HPV Vaccine as Need Factor 
The individual perceived need is based on view and experience on general health, 
functional state, and illness that prompt the use medical services (Babitsch et al., 2012). 
Anderson (1995) explained that perceived need is not primarily a gauge of disease, but 
health beliefs and social structure can expound a social phenomenon if adequately 
modeled. 
Andersen's BM was used to design and request information about adolescent 
interactions with the health care system and health providers (Massey et al., 2012). 
Massey et al. (2012) denoted that perceived need for well-care visits influenced the use of 
health care services. Massey et al. noted that most of the teens visited a provider only 
when they were ill or needed a sports physical. Although these adolescents had insurance 
coverage, underlying factor like perceived need could influence the use of the HPV 
vaccine, despite having access to a provider.  
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For this study, the perceived need for HPV vaccine was assessed by the rate of 
provider visit and the HPV vaccination rate. The need for HPV vaccine prompted the 
visit to the provider. In addition, 50% (APR = 1.56, 95% CI [1.20 -2.03]) of the sampled 
population visited the provider in the past 12 months, and 50% of adolescent females 
who visited their health care provider in the past 12 months were vaccinated for HPV and 
were 56% more likely to receive an HPV vaccination than those who did not visit their 
health care provider. 
Andersen (1995) identified that in promoting equitable access to health care use, a 
variable must point to changes in policy that could cause a change in behavior. I focused 
on a policy change (ACA) to determine if the change in policy influenced the use of HPV 
vaccine. I found there was a change in behavior, showed by increased provider visits and 
HPV vaccination rate. The rate of HPV vaccination increased among insured adolescent 
females in Georgia from 35.3% to 53.9% in 2015. Also, from 2011–2012, the HPV 
vaccination rate among the uninsured decreased from 43.7% to 25.3%, rose sharply to 
73.5% in 2013, and then declined to 18.0% in 2015.  
Among the three factors, predisposing, enabling, and need factors discussed under 
the Andersen’s BM, provider visit was statistically significantly associated with the ACA 
(P < 0.0001). Also, provider visit was statistically significantly associated with increased 
HPV vaccination rate (p <0.0002) among adolescent females in Georgia. I found that the 
ACA had a positive effect on HPV vaccination and significant effect on the rate of 
provider visit. However, the provider visit was the most significant influencing factor that 
impacted the use of the HPV vaccine usage among adolescent females in Georgia.  
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Limitations of the Study 
The limitations are discussed under the threats to validity, which consist of 
construct, internal, and external validity.  
Construct Validity 
The threat to the construct could arise from the structuring of the research 
questions based on available data, including inferring the result of RQ1 in the outcome 
finding. Nonresponse bias was noted, as 31.8% of the respondents did not respond to the 
question about health insurance. The bias was minimized through the multivariate 
analysis with a 95% CI. 
Internal Validity 
The internal validity referred to the validity of association with the result of this 
study. The threat to internal validity resulted from the data analysis on multiple years, 
2011 to 2015, population mobility from the relocation of residence, or scattering of 
records due to the use of more than one provider could result in underreporting of 
immunization records by providers. Also, a decrease in response rate can increase 
nonresponse bias. Nonresponse rate bias was noted in RQ1, where 31.8% of the 
respondents did not respond to the question pertaining to health insurance. The 
nonresponse rate introduced bias to the result, although the sampled population for 
analysis was n=1,500. However, the 95% CI indicated a positive association between the 
ACA and the HPV vaccination rate. 
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For this study, only a small set of variables was applied to Andersen's BM. Also, 
there were variations on how the variables were categorized and assessed, such as 
provider visit (enabling factor) and HPV vaccine (dependent variable and need factor). 
Educational and income levels were among the variables that were not assessed 
and analyzed in this study. A threat to the validity of association with the result of this 
study resulted from applying a small set of variables to the Andersen’s BM. 
External Validity 
The threat to external validity stemmed from having no indication if the sampled 
population included both rural and urban areas. The data were partly exported from the 
NIS-Teen data. The definition of adequate provider data used for 2014 NIS-Teen 
estimates was revised. This revision might affect vaccination coverage estimates, 
although the sampled population was 1,500. The outcomes of this study cannot be 
generalized.  
Recommendations 
This research was conducted because scholars have not examined if there was an 
association between health care reforms (ACA) with no cost-sharing for preventive 
services and HPV vaccination rate among adolescent females in Georgia. This study was 
necessary because underuse of HPV vaccine still exists in Georgia after the 
implementation of the ACA. Cost of the vaccine was noted to be a barrier, and no 
researcher explored if the ACA with no cost-sharing for preventive services had an 
impact on HPV vaccine usage. As lack of information existed regarding whether the 
ACA impacted the use of the HPV vaccine among adolescent females in Georgia. 
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This quantitative secondary data analysis has generated the need for future 
research. I recommend that another scholar statistically quantify if there is a real 
association between the ACA with the HPV vaccination rate among teenage females or 
provide insight into the magnitude of relationship and the problem in Georgia. This study 
should extend to both rural and urban Georgia adolescent females. The review should 
include the rate of vaccination based on dose series to determine the percentage of 
completion of the doses, which was not covered in this current study. 
Also, I used only a few variables that were applied to Andersen's BM of health 
care use. Future researchers need to evaluate multiple variables from the predisposing 
(such as education level), enabling (such as income level), and need factors to determine 
the most influencing factor as stipulated in the BM. A more comprehensive study of the 
application and operationalization of the BM that will minimize the variations on how the 
variables are categorized will provide a real picture of factors influencing the use of 
health services.   
Implications for Social Change 
I filled the gap identified in the literature, which was the primary focus of this 
study. This quantitative secondary data analysis of NIS Teen data from 2011–2015 
provided a broader view of the association between ACA (a new health policy) and the 
HPV vaccination rate among adolescent females in Georgia. In analyzing 5 years of data, 
I filled the literature gap by providing a statistically significant level of association.  
Further, I demonstrated the magnitude of the association between the ACA and 
provider visits, as well as the strong association between provider visits and the HPV 
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vaccination rate among adolescent females in Georgia. The research is the initial step in 
determining the factor based on Andersen's BM that has the most influence on health care 
use (HPV vaccine) among female teens in Georgia. Information on the degree of the 
association of the ACA on provider visits and the HPV vaccination rate is beneficial in 
creating awareness of the most effective means of enhancing the use of the HPV vaccine 
among this group to achieve 80% coverage and align with Healthy People’s 2020 goal for 
this population. Also, monitoring the trend of HPV vaccination from 2011 to 2015 helped 
in showing the underuse of the HPV vaccine among adolescent females in Georgia, 
despite the risk that HPV posed.  
HPV is the most frequent cause of STD in the young population that is sexually 
active (CDC, 2015). Latent effect of infections can result in genital warts and cervical 
and oropharyngeal cancers, which can be prevented through HPV vaccination during 
adolescence (Dunne et al., 2014). Other cancers that could result later are vaginal and 
vulvar cancers in women, anal types of cancer, and penile cancers in men (Meites et al., 
2016). In Georgia, the prevalence rate of cervical and oropharyngeal cancers linked to 
HPV was above the national average of 7.7% and 12.1% respectively (Berzen et al., 
2016). Also, the mortality rate for cervical cancer, oral cavity, and pharynx cancers were 
2.6% (National Cancer Institute, n.d.). Despite the higher incidence and mortality of both 
cervical and oropharyngeal cancers in Georgia, the HPV vaccination rate is still below 
the Healthy People 2020 goal of 80%. 
Effecting positive change will involve disseminating the results of this study, 
which can result in measures to be taken by policymakers, health care organizations, and 
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health care providers. The goal is to formulate an integrated approach that will include 
public policy, public health, and clinical medicine to develop strategies that will improve 
the use of the HPV vaccine among adolescent females to help attain the Healthy People 
2020 goal of 80% for this group. The social change implications resulting from this study 
will include creating awareness of the seriousness of the underuse of the HPV vaccine 
and the most effective factor identified by this study, which is offering the vaccine at 
every health encounter. This knowledge can enhance the ability of the health care 
providers to implement policies, protocols, and procedures that will optimize usage. 
The recommendations resulting from the findings of this study include healthcare 
providers formulating policies, protocols, and guidelines for screening for childhood 
immunization including HPV vaccine. Health care providers should create awareness and 
education on the risks associated with the HPV virus and the beneficial effect of the HPV 
vaccine to parents on every health encounter. Providers should offer/recommend the HPV 
vaccine at every health encounter, well or sick visits, to prevent missed opportunities.  
Policymakers should formulate policies that ensure the provisions of the ACA on 
no cost-sharing, infrastructures, preexisting conditions, and subsidies to purchase 
insurance at the marketplace and expand Medicaid to broaden access are not repealed. All 
of these measures will aid in the optimal use of the HPV vaccine to achieve 80% 
coverage and herd immunity. 
Achieving herd immunity through 80% of HPV vaccination coverage will result 
in the prevention of HPV-related infections, cancers, and the economic burdens 
associated with HPV. Having healthy adolescents will result in future healthier, 
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productive adults, community, and the entire population, which are outcomes of herd 
immunity. 
Conclusion 
HPV is the most frequent cause of STDs in the United States (Dunne et al., 2014). 
The youths ages15 to 24 accounts for half of the 20 million new STIs yearly, and one in 
four sexually active adolescent females have an STD associated with HPV (CDC, 2015). 
Latent effect of infections caused by HPV can result in genital warts and cervical and 
oropharyngeal cancers, which can be prevented through HPV vaccination during 
adolescence (Dunne et al., 2014).  
In Georgia, the prevalence rate of cervical and oropharyngeal cancers was above 
the national average at 7.7% and 12.1% respectively (Berzen et al., 2016). The mortality 
rate for cervical cancer, oral cavity, and pharynx cancers were 2.6% (National Cancer 
Institute, n.d.). Despite the higher incidence and mortality of both cervical and 
oropharyngeal cancers in Georgia, the HPV vaccination rate is below the Healthy People 
2020 goal of 80% after the implementation of the ACA. 
The ACA expanded access and allowed no cost-sharing for preventive services 
such as the HPV vaccine. In this quantitative secondary data analysis, there was a 
statistically significant strong association between the ACA and provider visits, 
subsequently provider visits and HPV vaccination rate. I recommend for health care 
providers to follow guidelines for screening for childhood immunization including HPV 
vaccine. Health care providers should create awareness and education on the risks 
associated with the HPV virus and the beneficial effect of the HPV vaccine to parents on 
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every health encounter. Providers should offer or recommend the HPV vaccine at every 
health encounter, well or sick visits, to prevent missed opportunities. Policymakers 
should formulate policies that will ensure the provisions of the ACA, such as no cost-
sharing, infrastructures, preexisting conditions, and subsidies to purchase insurance at the 
marketplace and expand Medicaid to broaden access. All of these measures will aid in the 
optimal use of HPV vaccine to achieve 80% coverage and herd immunity. 
The long-term outcome would include decreasing the rate of HPV-related 
infections and cancers, such as cervical cancer, and minimizing the financial burden 
related to HPV-related diseases and cancers. An additional outcome will be improved 
health and prosperity of individuals, including various communities in Georgia resulting 
from herd immunity. 
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Appendix A: NIS-TEEN Hard Copy Questionnaire Q4 2013 
Applicable sections are copied. See link for full hard-copy. 
Section S 
TIS_S1ADK 
Is there anyone in your household who knows how many people in this household who 
are less than 18 years old?  
NEW PERSON COMES TO PHONE ........... 1 GO TO TIS_DKINTRO 
NO................................................................... 2 GO TO TIS_S1TERM 
 
TIS_SELECTION_INSTRUCTIONS1 
 (1) IF YAGE_x >12 months and < 3 years THEN GO TO TIS_S2Q02A before going to 
S3_INTRO in NIS  
(2) ELSEIF ANY YAGE_x >12 and <18, THEN RANDOMLY SELECT ONE OF THE 
CHILDREN BETWEEN 13 AND 17 TO BE THE SELECTED CHILD FOR THE 
TEEN SURVEY AND GO TO TIS_S3INTRO 
(3) ELSE GO TO INSTRUCTION1 
TIS_S4  
Is the child born [insert month and year of birth] male or female? 
Male ................................................................ 1 GO TO CP_TISS5 
Female............................................................. 2 GO TO CP_TISS5 
DON’T KNOW............................................ 77 GO TO CP_TISS5 
REFUSED..................................................... 99 GO TO CP_TISS5 
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Section A 
TIS_AHPV_RECOM  
Has a doctor or other health care professional ever recommended that [TEEN] receive 
HPV shots?  
YES…………................................................. 1 GO TO TIS_AHPV_AGE  
NO………....................................................... 2 GO TO TIS_AHPV2  
DON’T KNOW…........................................ 77 GO TO TIS_AHPV2  
REFUSED………......................................... 99 GO TO TIS_ AHPV2  
 
TIS_AHPV_AGE  
At what age did the doctor or health care professional recommend that [TEEN] should 
start receiving the HPV shots?  
(01) BEFORE AGE 11  
(02) 11 OR 12 YEARS OF AGE  
(03) 13 OR 14 YEARS OF AGE  
(04) 15 OR 16 YEARS OF AGE  
(05) 17 OR 18 YEARS OF AGE  
(06) AFTER 18 YEARS OF AGE  
(07) NO SPECIFIC AGE WAS RECOMMENDED OR DISCUSSED  
(77) DON’T KNOW  
(99) REFUSED  
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TIS_AHPV2  
Looking at the shot record, please tell me how many times [TEEN] has received HPV 
shots?  
SHOTS…………........................................ ___ GO TO TIS_AHPV_DATE_X 
NONE………................................................. 0 GO TO TIS_AHPV_RECALL  
DON’T KNOW…........................................ 77 GO TO TIS_AHPV_RECALL  
REFUSED………. ........................................ 99 GO TO TIS_AHPV_RECALL 
TIS_AHPV_RECALL  
Did [TEEN] ever receive an HPV shot that is not on the shot record?  
YES………… ................................................. 1 GO TO TIS_AHPV_DOSE  
NO………. ..................................................... 2 F TIS_AHPV2 = (1-9, 50, 77, 99), GO 
TO TIS_AHPV_LOCATION; ELSE IF TIS_AHPV2 = 0, GO TO TIS_AHPV_INTENT. 
DON’T KNOW…. ....................................... 77 IF TIS_AHPV2 = (1-9, 50, 77, 99), GO 
TO TIS_AHPV_LOCATION; ELSE IF TIS_AHPV2 = 0, GO TO TIS_AHPV_INTENT. 
REFUSED………. .................................... ...99 IF TIS_AHPV2 = (1-9, 50, 77, 99), GO 
TO TIS_AHPV_LOCATION; ELSE IF TIS_AHPV2 = 0, GO TO TIS_AHPV_INTENT. 
TIS_AHPV_DOSE  
How many HPV shots did [TEEN] receive that are not on the shot record?  
SHOTS………… ........................................ ___  
ALL SHOTS………. .................................... 50  
DON’T KNOW…. ....................................... 77  
REFUSED………. ........................................ 99  
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IF TIS_S4 = 02, 77, 99, THEN DO:  
IF TIS_AHPV_DOSE=0 AND TIS_AHPV2 = (1-9, 50, 77, 99), GO TO 
TIS_AHPV_LOCATION; ELSE IF TIS_AHPV2 = 0, go to TIS_AHPV_INTENT IF 
TIS_AHPV_DOSE IN (1-9, 50, 77, 99), GO TO TIS_AHPV_REC_WHICH  
 
IF TIS_S4=01, THEN DO:  
IF TIS_AHPV_DOSE=0 AND TIS_AHPV2 = (1-9, 50, 77, 99), GO TO 
TIS_AHPV_LOCATION; ELSE IF TIS_AHPV2 = 0, go to TIS_AHPV_INTENT IF 
TIS_AHPV_DOSE IN (1-9, 50, 77, 99), GO TO TIS_AHPV_LOCATION 
Section B 
TIS_BHPV_AGE  
At what age did the doctor or health care professional recommend that [TEEN] should 
start receiving the HPV shots?  
(01) BEFORE AGE 11  
(02) 11 OR 12 YEARS OF AGE  
(03) 13 OR 14 YEARS OF AGE  
(04) 15 OR 16 YEARS OF AGE  
(05) 17 OR 18 YEARS OF AGE  
(06) AFTER 18 YEARS OF AGE  
(07) NO SPECIFIC AGE WAS RECOMMENDED OR DISCUSSED  
(77) DON’T KNOW  
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(99) REFUSED  
TIS_BHPV2  
Has [TEEN] ever received HPV shots?  
YES………… ................................................. 1 GO TO TIS_BHPV_DOSE  
NO………. ...................................................... 2 GO TO TIS_BHPV_INTENT  
DON’T KNOW…. ....................................... 77 GO TO TIS_BHPV_INTENT 
REFUSED………. ........................................ 99 GO TO TIS_BHPV_INTENT 
TIS_BHPV_DOSE  
How many HPV shots did [TEEN] ever receive?  
SHOTS………… ...................................... ____  
ALL SHOTS………. .................................... 50  
DON’T KNOW…. ....................................... 77  
REFUSED………. ........................................ 99  
(1) IF TIS_S4=02,77,99, THEN DO:  
IF TIS_BHPV_DOSE=0, GO TO TIS_BHPV_INTENT  
IF TIS_BHPV_DOSE IN (1-9, 50, 77,99), GO TO TIS_BHPV_WHICH 
(2)ELSE IF TIS_S4=01 THEN DO:  
IF TIS_BHPV_DOSE = 0, GO TO TIS_BHPV_INTENT  
IF TIS_BHPV_DOSE IN (1-9, 50, 77,99), GO TO TIS_BHPV_LOCATION 
TIS_BHPV_WHICH  
Which of the two HPV vaccines did your child receive?  
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Gardasil-The vaccine that protects against most cervical cancers, genital warts, and some 
other less common cancers ............................... …………...………............. 
...................……..1  
Cervarix--The vaccine that protects against most cervical 
cancers…………………………………………………......2  
BOTH GARDASIL AND CERVARIX………………………….. ...3  
DON’T KNOW…........................................ ..... ...............77  
REFUSED………. .......................................... .. ...............99  
 
ALL GO TO TIS_BHPV_LOCATION  
TIS_BHPV_LOCATION  
At what kind of place(s) did [TEEN] get [FILL: his/her] first HPV shot?  
[READ ONLY IF NECESSARY]  
(01) DOCTOR’S OFFICE  
(02) EMERGENCY ROOM  
(03) HEALTH DEPARTMENT  
(04) CLINIC OR HEALTH CENTER  
(05) HOSPITAL-BASED CLINIC  
(06) WHILE HOSPITALIZED  
(07) OTHER MEDICALLY-RELATED PLACE – GO TO TIS_BHPV_LOC_OTHER 
(08) PHARMACY, DRUG STORE, OR SUPERMARKET PHARMACY  
(09) WORKPLACE  
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(10) ELEMENTARY/MIDDLE/HIGH SCHOOL  
(11) OTHER NONMEDICALLY-RELATED PLACE – GO TO 
TIS_BHPV_LOC_OTHER  
(12) MALL OUTREACH [DISPLAY ONLY IF IAP=105]  
(13) VILLAGE OUTREACH [DISPLAY ONLY IF IAP=105  
 
(77) DON’T KNOW  
(99) REFUSED  
TIS_BHPV_LOC_OTHER 
 Other location: ____________________  
IF TIS_BHPV_DOSE > 1, THEN GO TO TIS_BHPV_LOCATION2. IF 
TIS_BHPV_DOSE < 1, GO TO TIS_BHPV_INTENT 52 
TIS_BHPV_LOCATION2  
Did [TEEN] receive all doses at the same location?  
(1) YES   IF TIS_BHPV_DOSE >= 3, GO TO TIS_BHPV_SAFE. IF F <3, 
GO TO TIS_BHPV_INTENT 
(2) NO   GO TO TIS_BHPV_LOCATION3  
(77) DON’T KNOW  IF TIS_BHPV_DOSE >= 3, GO TO TIS_BHPV_SAFE. IF <3, 
GO TO TIS_BHPV_INTENT 
(99) REFUSED   IF TIS_BHPV_DOSE >= 3, GO TO TIS_BHPV_SAFE. IF 
<3, GO TO TIS_BHPV_INTENT 
TIS_BHPV_LOCATION3 
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At what kind of place(s) did [TEEN] get [FILL his/her] second and third HPV shot(s)? 
[MAY GIVE MULTIPLE RESPONSES] 
[READ ONLY IF NECESSARY.] 
(01) DOCTOR’S OFFICE 
(02) EMERGENCY ROOM 
(03) HEALTH DEPARTMENT 
(04) CLINIC OR HEALTH CENTER 
(05) HOSPITAL-BASED CLINIC 
(06) WHILE HOSPITALIZED 
(07) OTHER MEDICALLY-RELATED PLACE GO TO 
TIS_BHPV_LOC3_OTHER 
(08) PHARMACY, DRUG STORE, OR SUPERMARKET PHARMACY 
(09) WORKPLACE 
(10) ELEMENTARY/MIDDLE/HIGH SCHOOL 
(11) OTHER NONMEDICALLY-RELATED PLACE GO TO  
(12) MALL OUTREACH [DISPLAY ONLY IF IAP=105] 
(13) VILLAGE OUTREACH [DISPLAY ONLY IF IAP=105 
(77) DON’T KNOW 
(99) REFUSED 
TIS_BHPV_LOC3_OTHER 
Other location: ____________________ 
IF TIS_BHPV_DOSE >=3 THEN GO TO TIS_BHPV_SAFE; ELSE GO TO 
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TIS_BHPV_INTENT. 
TIS_BHPV_PLAN_AGE 
At what age do you plan to have [TEEN] receive the HPV shots? 
_______ YEARS 
(1) NEVER/NO AGE GO TO TIS_BHPV_KNOWLEDGE 
(2) IT WILL BE MY CHILD’S DECISION IN THE FUTURE 
(77) DON’T KNOW 
(99) REFUSED 
TIS_BHPV_WHEN 
What is the MOST important factor that [FILL determined/will determine] WHEN 
[TEEN] [received/receives] the HPV shots? 
 
(1) DOCTOR RECOMMENDATION 
(2) BECOMES COMMON PRACTICE/BEEN STANDARD FOR 
YEARS/COMFORTABLE 
WITH RECOMMENDATION 
(3) WHEN I KNOW ENOUGH ABOUT HPV DISEASE AND THE VACCINE 
(4) MY TEEN ABOUT TO BECOME SEXUALLY ACTIVE 
(5) TEEN DECIDES AND WILLING TO RECEIVE VACCINE 
(6) TEEN AND I DECIDE TOGETHER TO GET VACCINE 
(7) INSURANCE COVERS THE COST/ NO COST CONCERNS 
(8) ENOUGH INFORMATION ABOUT VACCINE SAFETY 
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(9) CONVENIENT TO GO GET VACCINE/FIND TIME TO DO SO 
(10) SCHOOL REQUIREMENT 
(11) TEEN WILL NOT GET HPV VACCINE IN FUTURE 
(12) TEEN WILL NOT GET ANY VACCINES IN FUTURE 
(13) ALREADY SCHEDULED APPOINTMENT/ALREADY PLANNED 
(14) OTHER GO TO TIS_BHPV_WHEN_OTHER 
(77) DON'T KNOW 
(99) REFUSED 
TIS_BHPV_WHEN_OTHER. 
________________ 
GO TO TIS_BHPV_KNOWLEDGE 
Section E 
TIS_INS_11  
Since age 11 was there any time when [TEEN] was not covered by any health insurance 
for any reason? 
YES ................................................................. 1 
NO................................................................... 2 GO TO TIS_INS-13 
DON’T KNOW ............................................ 77 GO TO TIS_INS-13 
REFUSED..................................................... 99 GO TO TIS_INS-13 
TIS_C4 
“Is [TEEN] White, Black or African American, American Indian, Alaska Native, 
Asian, Native Hawaiian or other Pacific Islander”? 
